var title_f23_38_24160="Lichen planus arm";
var content_f23_38_24160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the shiny, flat, polygonal, violaceous papules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24160=[""].join("\n");
var outline_f23_38_24160=null;
var title_f23_38_24161="Irving tubal ligation A";
var content_f23_38_24161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Irving tubal ligation A",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tube is grasped with Babcock clamps.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24161=[""].join("\n");
var outline_f23_38_24161=null;
var title_f23_38_24162="Patient information: Small cell lung cancer (The Basics)";
var content_f23_38_24162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15812\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\">",
"         Normal lungs",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/34/35363\">",
"         Patient information: Lung cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/28/5570\">",
"         Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1076\">",
"         Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/8/22659\">",
"         Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Small cell lung cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/small-cell-lung-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1717804\">",
"      <span class=\"h1\">",
"       What is small cell lung cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Small cell lung cancer is one type of lung cancer. Lung cancer happens when normal lung cells change into abnormal cells and grow out of control (",
"      <a class=\"graphic graphic_figure graphicRef67527 \" href=\"UTD.htm?40/17/41237\">",
"       figure 1",
"      </a>",
"      ). There are different types of lung cancer. Some types grow faster than others.",
"     </p>",
"     <p>",
"      Small cell lung cancer usually grows fast. Most people who get small cell lung cancer are people who smoke or used to smoke.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717811\">",
"      <span class=\"h1\">",
"       What is lung cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out how far in your body a cancer has spread. To describe how far a person&rsquo;s small cell lung cancer has spread, doctors use the words &ldquo;limited&rdquo; or &ldquo;extensive.&rdquo;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        People with",
"        <strong>",
"         limited",
"        </strong>",
"        <strong>",
"         disease",
"        </strong>",
"        have lung cancer on one side of the chest, either in the right lung or in the left lung.",
"       </li>",
"       <li>",
"        People with",
"        <strong>",
"         extensive disease",
"        </strong>",
"        have lung cancer on both sides of the chest (in the right and left lungs). Or their lung cancer has spread to other parts of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the stage of your lung cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717818\">",
"      <span class=\"h1\">",
"       How is limited lung cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with limited small cell lung cancer are usually treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        &mdash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &mdash; Radiation kills cancer cells. Most people get radiation therapy at the same time as their chemotherapy treatment. But some people start radiation therapy after their chemotherapy is done. Usually, people have radiation aimed at the lungs. This can kill the cancer in the lungs. But people might also have radiation that is aimed at the brain, even if they do not have cancer in the brain. That&rsquo;s because brain radiation can reduce the chance that the cancer will spread to the brain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717825\">",
"      <span class=\"h1\">",
"       How is extensive lung cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with extensive small cell lung cancer are usually treated with chemotherapy. After chemotherapy, some people have treatment with radiation therapy to the lungs. Sometimes, people also have radiation therapy to the brain to prevent the cancer from spreading to the brain.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717832\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor will check every so often to see if your lung cancer has come back. Follow-up tests usually include exams and imaging tests such as chest x-rays or CT scans. Imaging tests can create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      In most people, small cell lung cancer comes back within 1 to 2 years.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717839\">",
"      <span class=\"h1\">",
"       What happens if the lung cancer comes back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the lung cancer comes back, you might get different chemotherapy medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717846\">",
"      <span class=\"h1\">",
"       What if I smoke?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you smoke, you should try to quit. People who survive lung cancer have a greater chance of getting lung cancer again if they smoke.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717853\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for lung cancer involves making many choices, such as what treatment to have and when.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Anytime you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1717980\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=see_link\">",
"       Patient information: Lung cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=see_link\">",
"       Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/28/5570?source=see_link\">",
"       Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"       Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/38/24162?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15812 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24162=[""].join("\n");
var outline_f23_38_24162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717804\">",
"      What is small cell lung cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717811\">",
"      What is lung cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717818\">",
"      How is limited lung cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717825\">",
"      How is extensive lung cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717832\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717839\">",
"      What happens if the lung cancer comes back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717846\">",
"      What if I smoke?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717853\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1717980\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15812\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\">",
"      Normal lungs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=related_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/28/5570?source=related_link\">",
"      Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=related_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=related_link\">",
"      Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_38_24163="Dermatitis herpetiformis elbows";
var content_f23_38_24163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesicles, bullae, erosions, and crusts on elbow skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24163=[""].join("\n");
var outline_f23_38_24163=null;
var title_f23_38_24164="Darier disease - light skin";
var content_f23_38_24164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Darier disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple yellow-brown hyperkeratotic papules are present on the chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24164=[""].join("\n");
var outline_f23_38_24164=null;
var title_f23_38_24165="Quantitative coronary angiography: Technical issues";
var content_f23_38_24165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Quantitative coronary angiography: Technical issues",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/38/24165/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24165/contributors\">",
"     Morton J Kern, MD, FSCAI, FAHA, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/38/24165/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24165/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/38/24165/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24165/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/38/24165/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduction in the coronary artery luminal cross-sectional diameter, estimated by the visual inspection of the radiocontrast column or lumenogram during conventional angiography, has been utilized to formulate predictions about clinical presentations and stress-induced reductions in coronary blood flow. Anatomic and physiologic approaches to coronary artery disease are complementary but because of numerous factors not evident from angiography (eg, length, entrance angle, coefficient of separation of laminar flow) comparison data yield contradictory results. As a result, quantitative approaches to the angiographic evaluation of coronary anatomy are infrequently employed on a routine daily basis in most laboratories. The greatest advantage of quantitative coronary angiography is its theoretical freedom from observer influences and bias, thereby minimizing significant potential intraobserver and interobserver variability.",
"   </p>",
"   <p>",
"    The technical issues related to quantitative coronary angiography will be reviewed here. The clinical utility of this procedure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29479?source=see_link\">",
"     \"Quantitative coronary angiography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many techniques are available for computer applications that permit quantification of coronary stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/1\">",
"     1",
"    </a>",
"    ]. A quantitative analysis of the angiogram requires some form of optical magnification of the cineangiographic image which, in turn, permits computer-assisted definition and quantitation of disease severity. With the off-line techniques, image acquisition proceeds in the conventional manner, with the generation of a digital cineangiogram displayed on the image processor. Digital quantitation of selected image frames can be made with or without electronic magnification, easily accomplished with modern digital quantitative software and analysis systems.",
"   </p>",
"   <p>",
"    A two times magnification factor is utilized in most laboratories, without regard to the optical system employed. The positioning of the camera and selection of the lens system is usually accomplished manually. After digitization, and prior to computer analysis, the images are stored in a specifically designed image processing system. These systems vary in complexity and cost, and are available with a large selection of hardware and software.",
"   </p>",
"   <p>",
"    On-line digital systems and computer application packages have become widely available through commercial distribution. These systems are designed to facilitate accurate clinical analysis of thrombolysis, stent deployment, and other endovascular interventions. The major impediment to universal application of on-line quantitation has been image quality. Recent advances in image-enhancement continue to refine the utility of on-line quantitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Edge-detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the image has been acquired and digitally processed, computer manipulation is performed. The most critical component of the computational analysis is the algorithm of boundary delineation within the area of interest. This method requires identification of the arterial segment to be analyzed and an accurate computer-assisted vessel edge delineation (",
"    <a class=\"graphic graphic_figure graphicRef71072 \" href=\"UTD.htm?37/60/38862\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The identification of the segment-of-interest can be automated, semiautomated, or manual. The operator may interactively indicate windows of interest [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/2\">",
"     2",
"    </a>",
"    ], approximate borders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/3\">",
"     3",
"    </a>",
"    ], or points along the center line of the vascular segment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/4\">",
"     4",
"    </a>",
"    ]. More fully automated techniques are also available, in which the arterial center line is computed after manual assignment of the visually derived center of the vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, edge definition, which is more important to quantitation, is less easily accomplished. A manual technique can be used in the absence of computer manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/6\">",
"     6",
"    </a>",
"    ]. More elaborate algorithms can also be applied to this task, including first derivative, second derivative, and first semiderivative functions.",
"   </p>",
"   <p>",
"    To derive quantitatively useful information from the arterial segment analysis, a calibration function converts measured pixels to in vivo millimeters, utilizing reference standards derived from the contrast filled catheter. Known spacing distances between radiopaque markers on specially manufactured catheters, or upon the measured diameter of carefully placed cylindrical markers along the body of the catheter are frequently used [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/7\">",
"     7",
"    </a>",
"    ]. More often, the known diameter of the angiographic catheter is used for the automated edge-detection of a defined catheter segment or manual delineation of the catheter boundaries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Utilizing internal calibration from geometric analysis of biplane images, the errors of differential magnification can be potentially averted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Densitometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The densitometric methodology minimizes any distorting effect of lesional eccentricities upon those geometric assumptions which are required for area calculations by the edge-detection methods. With densitometry, assuming homogeneous distribution of radio-contrast in the blood pool, the errors in edge definition are minimized since the method utilizes the measurement of brightness profiles throughout the segmental diameters which surround the defined center line [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/9\">",
"     9",
"    </a>",
"    ]. With application of this assumption, the difference in cross-sectional luminal area can be compared between normal and diseased vascular segments, using differences in the density of radio-contrast distributed within each cross-sectional area. These derived measurements must be corrected for radiation scatter by the subtraction of background activity. Additional radiographic variables can contribute to measurement inaccuracy, and convincing validation of this technique has not yet been forthcoming.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Comparison of densitometric QCA with edge-detection and intracoronary ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is generally good agreement between edge-detection QCA and intracoronary ultrasound when normal coronary segments are evaluated. However, although edge-detection QCA is often used after angioplasty, it may not be accurate when complex lesion morphology results from the procedure, as irregularities in the new lumen due to disruption of the plaque may interfere with quantification. Use of QCA is often applied to lumen assessment after stenting, although the analysis is at times confounded by the same variables of image quality such as calcifications and stent struts. Densitometric QCA may be less vulnerable to inaccuracy. To further evaluate the role of densitometric QCA, one study compared measurements obtained with intracoronary ultrasound, edge-detection QCA, and densitometric QCA performed after angioplasty in 161 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/10\">",
"     10",
"    </a>",
"    ]. Luminal dimensions, as obtained from densitometric QCA, matched those from intracoronary ultrasound more closely than those from edge-detection QCA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     QUANTITATIVE ANGIOGRAPHIC PARAMETERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional standard cineangiography provides a diagnosis and stratification of coronary disease based upon the degree of vessel narrowing relative to an assumed normal vessel diameter. Quantitative coronary angiography (QCA) reports the percent diameter stenosis as well as additional parameters, such as lesion length, area of obstruction, area of plaque, and minimal stenosis diameter. Hemodynamic parameters, such as resistance to flow and derived transluminal pressure gradients, have been calculated but bear little accuracy relative to direct intracoronary measurements. All of these quantitative manipulations are rendered more difficult when the vessel is diffusely diseased, which is common, and there are confounding effects of long segments of ectasia and atherosclerotic disease.",
"   </p>",
"   <p>",
"    The reference diameter and the diameter of the diseased segment may change in response to pharmacologic or endovascular intervention. To minimize resultant variability and measurement error, the minimal obstruction diameter of the lesion is reported in addition to the standard percent diameter stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/11\">",
"     11",
"    </a>",
"    ]. Several methods to calculate the minimal lumen diameter have been defined using the diameter of the normal reference segment in a user-independent fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/12\">",
"     12",
"    </a>",
"    ]. Quantitative analysis of long arterial segments has objectified diffuse disease, but this approach has not been universally accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VALIDATION STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Validation of the techniques of QCA entails documentation of the accuracy, precision, and reproducibility of the numerical estimates of coronary artery dimensions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/14\">",
"     14",
"    </a>",
"    ]. It has been proposed that the accuracy of quantitation can be determined from the mean differences in measurements, while the precision of the methodology is related to the standard deviation of the measured differences, either among repeated analyses of the same vascular dimension or, in the case of experimental model systems, between measured and actual values [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, in order to assess reproducibility, it has been suggested that a standardized series of angiographic studies be utilized within each laboratory, thereby quantitating interobserver and intraobserver variability.",
"   </p>",
"   <p>",
"    Validation studies of the off-line edge detection techniques have utilized a number of experimental approaches. In radiographic \"phantom studies,\" \"stenoses\" of known dimensions (typically 0.5 to 5.0 mm) are fashioned from nonbiologic materials filled with radio-contrast agents and imaged angiographically. Results of these studies generally predict an accuracy of approximately 0.03 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/16\">",
"     16",
"    </a>",
"    ]. Post-mortem studies provide a further source of in vivo validation; such studies typically describe correlation coefficients of &gt;0.9 between actual necropsy dimensions and the measured values by angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observed relative absence of variability after serial quantitative analysis of a single coronary angiographic study is also promising: mean differences in the predicted minimal stenosis diameter of approximately 0.10 mm have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/16\">",
"     16",
"    </a>",
"    ]. Validation studies have been conducted for video densitometry as well, including necropsy studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/17\">",
"     17",
"    </a>",
"    ] and the study of phantom lesions within animal vascular systems [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The experimental placement and on-line assessment of phantom stenoses within porcine coronary arteries yielded measured mean deviations of 0.08 to 0.15 mm from the true stenosis diameters, whose known dimensions ranged from 0.5 to 1.9 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For in vivo clinical applications, serial assessment of changes in lumen diameter indicate a threshold for angiographically detectability of 0.44 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/21\">",
"     21",
"    </a>",
"    ]. A similar angiographic threshold for detectable true",
"    <span class=\"nowrap\">",
"     progression/regression",
"    </span>",
"    (0.40 mm) has been described in a cohort of men followed prospectively after coronary bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/22\">",
"     22",
"    </a>",
"    ]. When vasomotor responses are minimized with pretreated with nitrates, 24-hour follow-up studies after percutaneous coronary angioplasty indicate that the mean difference in measured minimal luminal diameter varied by only 0.20 mm, a reproducible threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/23\">",
"     23",
"    </a>",
"    ]. This study is in contrast to an observed significant increase in diameter percent stenosis representing the corresponding increase in the reference diameter of the normal segment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another source of in vivo validation, albeit indirect, is provided by the high correlation between the transstenotic pressure gradients derived from QCA and clinical observations during exercise myocardial scintigraphy using thallium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/25\">",
"     25",
"    </a>",
"    ]. Automated angiographic measurements also correlate well with the results of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography. In this context, a minimal luminal diameter of 1.07 mm strongly predicts the likelihood of an abnormal functional response to dobutamine infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24165/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9429751\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Quantitative coronary angiography (QCA) is a method to provide more objective interpretation of the coronary lumenogram than standard visual estimation. The greatest advantage of quantitative coronary angiography is its theoretical freedom from observer influences and bias, thereby minimizing significant potential intraobserver and interobserver variability.",
"     </li>",
"     <li>",
"      QCA reports the percent diameter stenosis as well as additional parameters, such as lesion length, area of obstruction, area of plaque, and minimal stenosis diameter.",
"     </li>",
"     <li>",
"      QCA attempts to standardize the measurement of stenosis severity.",
"     </li>",
"     <li>",
"      QCA has been utilized to formulate predictions about clinical presentations and prognosis.",
"     </li>",
"     <li>",
"      Quantitative approaches to the angiographic evaluation of coronary anatomy are infrequently employed on a routine daily basis in most laboratories.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/1\">",
"      Reiber, JH, Kooijman, CJ, Slager, CJ, et al. Computer-assisted analysis of the severity of obstructions from coronary cineangiograms: A methodological review. Automedica 1984; 5:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/2\">",
"      Nichols AB, Gabrieli CF, Fenoglio JJ Jr, Esser PD. Quantification of relative coronary arterial stenosis by cinevideodensitometric analysis of coronary arteriograms. Circulation 1984; 69:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/3\">",
"      Ellis S, Sanders W, Goulet C, et al. Optimal detection of the progression of coronary artery disease: comparison of methods suitable for risk factor intervention trials. Circulation 1986; 74:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/4\">",
"      Kirkeeide, RL, Fung, P, Smalling, RW, Gould, KL. Automated evaluation of vessel diameter from arteriograms. Comput Cardiol 1982; 5:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/5\">",
"      LeFree MT, Simon SB, Lewis RJ, et al.. Digital radiographic coronary artery quantification. Comput Cardiol 1985; 99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/6\">",
"      Brown BG, Bolson E, Frimer M, Dodge HT. Quantitative coronary arteriography: estimation of dimensions, hemodynamic resistance, and atheroma mass of coronary artery lesions using the arteriogram and digital computation. Circulation 1977; 55:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/7\">",
"      Sanders, WJ, Alderman, EL, Harrison, DC. Coronary artery quantitation using digital image processing techniques. Comput Cardiol 1979; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/8\">",
"      Wollschlager H, Lee P, Zeiher A, et al.. Improvement of quantitative angiography by exact calculation of radiological magnification factors. Comput Cardiol 1985; 483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/9\">",
"      Serruys PW, Reiber JH, Wijns W, et al. Assessment of percutaneous transluminal coronary angioplasty by quantitative coronary angiography: diameter versus densitometric area measurements. Am J Cardiol 1984; 54:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/10\">",
"      Peters RJ, Kok WE, Pasterkamp G, et al. Videodensitometric quantitative angiography after coronary balloon angioplasty, compared to edge-detection quantitative angiography and intracoronary ultrasound imaging. Eur Heart J 2000; 21:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/11\">",
"      Beatt KJ, Luijten HE, de Feyter PJ, et al. Change in diameter of coronary artery segments adjacent to stenosis after percutaneous transluminal coronary angioplasty: failure of percent diameter stenosis measurement to reflect morphologic changes induced by balloon dilation. J Am Coll Cardiol 1988; 12:315.",
"     </a>",
"    </li>",
"    <li>",
"     Reiber JHC, Serruys PW, Slager CJ. Quantitative Coronary and Left Ventricular Cineangiography: Methodology and Clinical Applications, Martinus Nijhoff, Boston 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/13\">",
"      Crawford DW, Brooks SH, Selzer RH, et al. Computer densitometry for angiographic assessment of arterial cholesterol content and gross pathology in human atherosclerosis. J Lab Clin Med 1977; 89:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/14\">",
"      Reiber JH, Kooijman CJ, Slager CJ, et al. Coronary artery dimensions from cineangiograms methodology and validation of a computer-assisted analysis procedure. IEEE Trans Med Imaging 1984; 3:131.",
"     </a>",
"    </li>",
"    <li>",
"     Reiber JHC. Morphologic and densitometric quantitation of coronary stenoses: An overview of existing quantitation techniques. In: New Developments in Quantitative Coronary Arteriography, Reiber JHC, Serruys PW (Eds), Martinus Nijhoff, Dordrecht 1988. p.34.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/16\">",
"      Kishon Y, Yerushalmi S, Deutsch V, Neufeld HN. Measurement of coronary arterial lumen by densitometric analysis of angiograms. Angiology 1979; 30:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/17\">",
"      Doriot PA, Suilen C, Guggenheim N, et al. Morphometry versus densitometry--a comparison by use of casts of human coronary arteries. Int J Card Imaging 1992; 8:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/18\">",
"      Di Mario C, Haase J, den Boer A, et al. Edge detection versus densitometry in the quantitative assessment of stenosis phantoms: an in vivo comparison in porcine coronary arteries. Am Heart J 1992; 124:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/19\">",
"      Mancini GB, Simon SB, McGillem MJ, et al. Automated quantitative coronary arteriography: morphologic and physiologic validation in vivo of a rapid digital angiographic method. Circulation 1987; 75:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/20\">",
"      Haase J, Di Mario C, Slager CJ, et al. In-vivo validation of on-line and off-line geometric coronary measurements using insertion of stenosis phantoms in porcine coronary arteries. Cathet Cardiovasc Diagn 1992; 27:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/21\">",
"      Reiber JH, Serruys PW, Kooijman CJ, et al. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation 1985; 71:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/22\">",
"      Syv&auml;nne M, Nieminen MS, Frick MH. Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery. A validation study. Int J Card Imaging 1994; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/23\">",
"      Foley DP, Deckers J, van den Bos AA, et al. Usefulness of repeat coronary angiography 24 hours after successful balloon angioplasty to evaluate early luminal deterioration and facilitate quantitative analysis. Am J Cardiol 1993; 72:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/24\">",
"      Foley DP, Escaned J, Strauss BH, et al. Quantitative coronary angiography (QCA) in interventional cardiology: clinical application of QCA measurements. Prog Cardiovasc Dis 1994; 36:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/25\">",
"      Wijns W, Serruys PW, Reiber JH, et al. Quantitative angiography of the left anterior descending coronary artery: correlations with pressure gradient and results of exercise thallium scintigraphy. Circulation 1985; 71:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24165/abstract/26\">",
"      Baptista J, Arnese M, Roelandt JR, et al. Quantitative coronary angiography in the estimation of the functional significance of coronary stenosis: correlations with dobutamine-atropine stress test. J Am Coll Cardiol 1994; 23:1434.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1518 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24165=[""].join("\n");
var outline_f23_38_24165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9429751\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Edge-detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Densitometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Comparison of densitometric QCA with edge-detection and intracoronary ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      QUANTITATIVE ANGIOGRAPHIC PARAMETERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VALIDATION STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9429751\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1518\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1518|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/60/38862\" title=\"figure 1\">",
"      Edge detection angiography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29479?source=related_link\">",
"      Quantitative coronary angiography: Clinical applications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_38_24166="Acute fatty liver of pregnancy";
var content_f23_38_24166=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute fatty liver of pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/38/24166/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24166/contributors\">",
"     Yannick Bacq, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/38/24166/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24166/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24166/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/38/24166/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24166/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/38/24166/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute fatty liver of pregnancy, characterized by microvesicular fatty infiltration of hepatocytes, is a disorder which is unique to human pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/1\">",
"     1",
"    </a>",
"    ]. It was described in 1940 and was initially thought to be universally fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/2\">",
"     2",
"    </a>",
"    ]. However, early diagnosis and prompt delivery have dramatically improved the prognosis, and maternal mortality should now be the exception rather than the rule [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major clinical features of acute fatty liver of pregnancy will be reviewed here. A general approach to the pregnant woman who develops liver disease is presented elsewhere and has also been addressed in a guideline issued by the American College of Gastroenterology (",
"    <a class=\"graphic graphic_table graphicRef72172 \" href=\"UTD.htm?22/53/23387\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26198?source=see_link\">",
"     \"Approach to liver disease occurring during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute fatty liver of pregnancy is rare with an approximate incidence of 1 in 7000 to 1 in 20,000 deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. It is more common with multiple gestations and possibly in women who are underweight.",
"   </p>",
"   <p>",
"    One of the largest population-based studies included 1,132,964 pregnancies at 229 hospitals in the United Kingdom between 2005 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/8\">",
"     8",
"    </a>",
"    ]. There were a total of 57 women diagnosed with acute fatty liver of pregnancy (5 cases per 100,000 pregnancies, 95% CI 3.8-6.5). Of these, 18 percent of women had twin pregnancies and 20 percent were underweight (body mass index &lt;20).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute fatty liver occurs typically in the third trimester. The disease is always present before delivery, although it is not always diagnosed prior to delivery.",
"   </p>",
"   <p>",
"    The most frequent initial symptoms are nausea or vomiting (approximately 75 percent of patients), abdominal pain (particularly epigastric, 50 percent), anorexia, and jaundice. About one-half of patients have signs of preeclampsia at presentation or at some time during the course of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extrahepatic complications can occur. In one series of 32 cases with severe liver dysfunction requiring admission to a liver failure unit, infection occurred in 17 and major intraabdominal bleeding in 10, some of whom required surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/10\">",
"     10",
"    </a>",
"    ]. Transient polyuria and polydipsia due to central diabetes insipidus also can be seen; the mechanism is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/11\">",
"     11",
"    </a>",
"    ]. Rare patients develop pancreatitis, which can be severe. Pancreatitis generally becomes apparent only after development of hepatic and renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with acute fatty liver of pregnancy have abnormal liver tests, with the serum aminotransferase elevations ranging from modest values up to 1000",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    Serum bilirubin levels are also usually elevated. The white blood cell count may be higher than is usually seen in pregnancy, a change that is nonspecific. The platelet count may be decreased with or without other signs of disseminated intravascular coagulation (DIC) which is associated with marked reduction in antithrombin III&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/13\">",
"     13",
"    </a>",
"    ]. Severely affected patients also have elevations in serum ammonia, prolongation of prothrombin time, and hypoglycemia caused by hepatic insufficiency. Acute renal failure and hyperuricemia are often present [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association of cases of acute fatty liver of pregnancy with one of the inherited defects in mitochondrial beta-oxidation of fatty acids, long-chain 3-hydroxyacyl CoA dehydrogenase deficiency (LCHAD), suggested that some affected women and their fetuses might have an inherited enzyme deficiency in beta-oxidation that predisposes the mother to this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LCHAD catalyzes the third step in the beta-oxidation of fatty acids in mitochondria (the formation of 3-ketoacyl-CoA from 3-hydroxyacyl-CoA). The accumulation of long-chain 3-hydroxyacyl metabolites produced by the fetus or placenta is toxic to the liver and may be the cause of the liver disease.",
"   </p>",
"   <p>",
"    The role of LCHAD in the pathogenesis of acute fatty liver of pregnancy has been illustrated in a number of studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 12 women with a previous episode of acute fatty liver of pregnancy, eight had evidence of being heterozygous for LCHAD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/18\">",
"       18",
"      </a>",
"      ]. These eight women had nine pregnancies complicated by fatty liver; seven of these pregnancies were also associated with preeclampsia and HELLP (presumably stressing the woman's compromised beta-oxidation function) and seven of the nine offspring were proven or presumed to be homozygous deficient (spilling unmetabolized long chain fatty acids into the maternal circulation). The other two offspring had heterozygous LCHAD.",
"     </li>",
"     <li>",
"      One series focused on three families with children presenting with sudden unexplained death or hypoglycemia and elevated liver enzymes (Reye-like syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/19\">",
"       19",
"      </a>",
"      ]. In all families, the mothers had acute fatty liver of pregnancy during the pregnancies with the affected infants. Three children who were studied had mutations in both alleles for long-chain 3-hydroxyacyl CoA dehydrogenase.",
"     </li>",
"     <li>",
"      The effects of fetal genotype on maternal and fetal outcomes were evaluated in 35 families with mitochondrial trifunctional protein mutations in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/20\">",
"       20",
"      </a>",
"      ]. Approximately one-half of women who carried affected fetuses had acute fatty liver of pregnancy, and 11 percent had a HELLP syndrome. All women who had a maternal illness carried fetuses with isolated long-chain 3-hydroxyacyl-coA dehydrogenase deficiency. No maternal or fetal complications were associated with heterozygous or wild-type fetal genotypes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some investigators have not been able to confirm the association with LCHAD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. One possible explanation is that only specific genetic defects associated with LCHAD lead to an increased risk of acute fatty liver of pregnancy. This hypothesis was evaluated in a study that included 24 children with 3-hydroxyacyl-CoA deficiency in whom nucleotide-sequence analysis was used to identify mutations in the alpha subunit of a trifunctional protein [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/23\">",
"     23",
"    </a>",
"    ], which is associated with the inner mitochondrial membrane and provides the active site for LCHAD activity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Nineteen children were either homozygotes for the G1528C mutation in which glutamic acid was replaced with glutamine (E474Q) or compound heterozygotes (with the glutamine mutation plus a different mutation on the other allele). Fifteen mothers of these children (79 percent) developed acute fatty liver of pregnancy, the HELLP syndrome, or both. In contrast, pregnancy-related liver disease was not observed during pregnancies in children who had other mutations or in pregnancies in which the fetus had at least one wild-type allele. Another possible explanation for the absence of detectable LCHAD mutations is that other defects in beta oxidation of fatty acids have been described in association with acute fatty liver of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of children with LCHAD deficiency born to mothers with acute fatty liver of pregnancy was estimated in a cohort study that included 108 consecutive blood samples from women who developed acute fatty liver or HELLP syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/27\">",
"     27",
"    </a>",
"    ]. Mutations causing LCHAD deficiency were detected in 19 percent of women with a maternal history of fatty liver but only one woman with HELLP syndrome. The most common maternal mutation was the mutation G1528C mutation which alters amino acid 474 from glutamic acid to glutamine on the protein (E474Q). Testing for the known genetic variants of this LCHAD is available and should be considered in affected women, their infants, and fathers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/19,25,28\">",
"     19,25,28",
"    </a>",
"    ]. However, testing only for the G1528C mutation does not rule out LCHAD deficiency, which may be caused by a number of other mutations.",
"   </p>",
"   <p>",
"    When stressed, infants with LCHAD are at risk to develop fatal nonketotic hypoglycemia, imitating Reye's syndrome or defects in urea cycle function [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, some forms of LCHAD deficiency are associated with neonatal dilated cardiomyopathy or progressive neuromyopathy. In one report, these features were observed in five children who had complete deficiency of the mitochondrial trifunctional protein required for 3-hydroxyacyl-CoA dehydrogenase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the diagnosis of LCHAD-deficiency in the newborn can be life-saving, all women with acute fatty liver of pregnancy and their children should undergo molecular testing for LCHAD, at least for the most common G1528C mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Testing is commercially available (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab?db=genetests\">",
"     file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab?db=genetests",
"    </a>",
"    ) and should be coordinated with a metabolic or genetic specialist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute fatty liver of pregnancy is usually made clinically based upon the setting, presentation, and compatible laboratory and imaging results. Laboratory tests that are helpful include serum aminotransferases, serum bilirubin, coagulation studies, electrolytes, serum glucose, uric acid level and creatinine, and a white blood cell count.",
"   </p>",
"   <p>",
"    The major other condition that must be excluded is the HELLP syndrome, which is characterized by hemolysis, elevated liver enzymes, and a low platelet count. There is a large clinical overlap between AFLP and HELLP syndrome and it may be difficult, even impossible, to differentiate them. However, evidence of hepatic insufficiency such as hypoglycemia or encephalopathy is suggestive of AFLP. In one series of 46 women who developed liver disease during pregnancy severe enough to require admission to a liver failure unit, 70 percent had acute fatty liver and 15 percent had HELLP [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/10\">",
"     10",
"    </a>",
"    ]. Most of the remaining patients had liver disease that was unrelated to pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging tests of the liver are primarily used to exclude other diagnoses, such as a hepatic infarct or hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/31\">",
"     31",
"    </a>",
"    ]. Some authors have reported finding fat on either ultrasonography or computed tomography, but these tests are most useful in retrospect, when comparing the images obtained during the height of the illness with those obtained several months later [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver biopsy is diagnostic, showing the characteristic picture which is the microvesicular fatty infiltration of the hepatocytes. The fat droplets surround centrally located nuclei, giving the cytoplasm a foamy appearance. The fatty infiltration is prominent in central and mid zonal parts of the lobule and usually spares a sharply defined rim of cells around the portal tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/34\">",
"     34",
"    </a>",
"    ]. Tissue should be set aside at the time of the procedure for special stains (oil red O on frozen section, or electron microscopy) for confirmation of diagnosis in patients without evident vacuolization (",
"    <a class=\"graphic graphic_picture graphicRef68144 \" href=\"UTD.htm?15/15/15606\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Because liver biopsy is invasive, it is not always performed. Liver biopsy should be approached with caution during pregnancy, and reserved for cases in which the diagnosis is in doubt and the appropriate treatment (delivery) is being delayed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT AND COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific medical treatment for acute fatty liver of pregnancy. As a result, the primary treatment is prompt delivery, usually emergently, after maternal stabilization.",
"   </p>",
"   <p>",
"    Maternal stabilization requires glucose infusion and reversal of coagulopathy (eg, administration of fresh frozen plasma, cryoprecipitate, packed red blood cells and platelets), as needed. Attention should be paid to the women's overall fluid status because the low plasmatic oncotic pressure can lead to pulmonary edema. Hypoglycemia is common and all patients should have glucose monitored until normal liver function returns [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/7\">",
"     7",
"    </a>",
"    ]. We typically treat hypoglycemia with a continuous infusion of 10 percent dextrose solution. Some patients with severe hypoglycemia may require multiple supplementary ampules of 50 percent dextrose [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The liver tests and coagulopathy usually start to normalize shortly after delivery. A transient worsening of liver and renal functions and coagulopathy may be observed during the first few days after delivery followed by a definitive improvement. In most severe cases, mostly when diagnosis has been delayed, there may be many more days of illness requiring maximal supportive management in an intensive care unit, including mechanical ventilation because of coma, dialysis for acute renal failure, parenteral nutrition because of associated pancreatitis, or even surgery to treat bleeding from a preceding cesarean section.",
"   </p>",
"   <p>",
"    Most severely ill patients recover and have no sequelae of the liver disease itself [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/7\">",
"     7",
"    </a>",
"    ]. However, substantial morbidity and mortality can occur. In a population-based study that included 57 patients with acute fatty liver of pregnancy, one woman required a liver transplant and one woman died (case fatality rate of 1.8 percent, 95% CI 0 to 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/8\">",
"     8",
"    </a>",
"    ]. There were seven deaths among 67 infants (perinatal mortality rate of 104 per 1000 births, 95% CI 32 to 203). Other reports have also described patients who required liver transplantation but it is unlikely to be needed with early diagnosis and prompt delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute fatty liver can recur in subsequent pregnancies, even if the search of LCHAD mutation is negative [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24166/abstract/6,15,18,22,39-41\">",
"     6,15,18,22,39-41",
"    </a>",
"    ]. However, the exact risk of recurrence is unknown. Affected women should be warned of this possibility and subsequent pregnancies can be undertaken provided that the woman understands the risks. Such patients should be monitored by an expert in maternal-fetal medicine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116577307\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute fatty liver of pregnancy, characterized by microvesicular fatty infiltration of hepatocytes, is a disorder which is unique to human pregnancy. It is rare, with an approximate incidence of 1 in 7000 to 1 in 20,000 deliveries. It is more common with multiple gestations and possibly in women who are underweight. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute fatty liver occurs typically in the third trimester. The disease is always present before delivery, although it is not always diagnosed prior to delivery. The most frequent initial symptoms are nausea or vomiting (approximately 75 percent of patients), abdominal pain (particularly epigastric, 50 percent), anorexia, and jaundice. About one-half of patients have signs of preeclampsia at presentation or at some time during the course of illness. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acute fatty liver of pregnancy is usually made clinically based upon the setting, presentation, and compatible laboratory and imaging results. Laboratory tests that are helpful include serum aminotransferases, serum bilirubin, coagulation studies, electrolytes, serum glucose, uric acid level and creatinine, and a white blood cell count. The major other condition that must be excluded is the HELLP syndrome, which is characterized by hemolysis, elevated liver enzymes, and a low platelet count. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific medical treatment for acute fatty liver of pregnancy. As a result, the primary treatment is prompt delivery, usually emergently, after maternal stabilization. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment and course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The association of cases of acute fatty liver of pregnancy with one of the inherited defects in mitochondrial beta-oxidation of fatty acids, long-chain 3-hydroxyacyl CoA dehydrogenase deficiency (LCHAD), suggested that some affected women and their fetuses might have an inherited enzyme deficiency in beta-oxidation that predisposes the mother to this disorder. We suggest that all women with acute fatty liver of pregnancy and their children undergo molecular testing for LCHAD, at least for the most common G1528C mutation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Testing is commercially available (",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab?db=genetests\">",
"       file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab?db=genetests",
"      </a>",
"      ) and should be coordinated with a metabolic or genetic specialist. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute fatty liver can recur in subsequent pregnancies, even if the search of LCHAD mutation is negative. Women with a history of acute fatty liver who are contemplating pregnancy should be monitored by an expert in maternal-fetal medicine. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Recurrence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112472687\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/1\">",
"      Bacq Y, Riely CA. Acute fatty liver of pregnancy: the hepatologist's view. Gastroenterologist 1993; 1:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/2\">",
"      Sheehan H. The pathology of acute yellow atrophy and delayed chloroform poisoning. J Obstet Gynaecol 1940; 47:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/3\">",
"      Riely CA. Liver disease in the pregnant patient. American College of Gastroenterology. Am J Gastroenterol 1999; 94:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/4\">",
"      Usta IM, Barton JR, Amon EA, et al. Acute fatty liver of pregnancy: an experience in the diagnosis and management of fourteen cases. Am J Obstet Gynecol 1994; 171:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/5\">",
"      Pockros PJ, Peters RL, Reynolds TB. Idiopathic fatty liver of pregnancy: findings in ten cases. Medicine (Baltimore) 1984; 63:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/6\">",
"      Reyes H, Sandoval L, Wainstein A, et al. Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients. Gut 1994; 35:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/7\">",
"      Castro MA, Fassett MJ, Reynolds TB, et al. Reversible peripartum liver failure: a new perspective on the diagnosis, treatment, and cause of acute fatty liver of pregnancy, based on 28 consecutive cases. Am J Obstet Gynecol 1999; 181:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/8\">",
"      Knight M, Nelson-Piercy C, Kurinczuk JJ, et al. A prospective national study of acute fatty liver of pregnancy in the UK. Gut 2008; 57:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/9\">",
"      Riely CA. Acute fatty liver of pregnancy. Semin Liver Dis 1987; 7:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/10\">",
"      Pereira SP, O'Donohue J, Wendon J, Williams R. Maternal and perinatal outcome in severe pregnancy-related liver disease. Hepatology 1997; 26:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/11\">",
"      Kennedy S, Hall PM, Seymour AE, Hague WM. Transient diabetes insipidus and acute fatty liver of pregnancy. Br J Obstet Gynaecol 1994; 101:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/12\">",
"      Moldenhauer JS, O'brien JM, Barton JR, Sibai B. Acute fatty liver of pregnancy associated with pancreatitis: a life-threatening complication. Am J Obstet Gynecol 2004; 190:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/13\">",
"      Castro MA, Goodwin TM, Shaw KJ, et al. Disseminated intravascular coagulation and antithrombin III depression in acute fatty liver of pregnancy. Am J Obstet Gynecol 1996; 174:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/14\">",
"      Gr&uuml;nfeld JP, Pertuiset N. Acute renal failure in pregnancy: 1987. Am J Kidney Dis 1987; 9:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/15\">",
"      Schoeman MN, Batey RG, Wilcken B. Recurrent acute fatty liver of pregnancy associated with a fatty-acid oxidation defect in the offspring. Gastroenterology 1991; 100:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/16\">",
"      Wilcken B, Leung KC, Hammond J, et al. Pregnancy and fetal long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency. Lancet 1993; 341:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/17\">",
"      Treem WR, Rinaldo P, Hale DE, et al. Acute fatty liver of pregnancy and long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Hepatology 1994; 19:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/18\">",
"      Treem WR, Shoup ME, Hale DE, et al. Acute fatty liver of pregnancy, hemolysis, elevated liver enzymes, and low platelets syndrome, and long chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Am J Gastroenterol 1996; 91:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/19\">",
"      Sims HF, Brackett JC, Powell CK, et al. The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci U S A 1995; 92:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/20\">",
"      Yang Z, Zhao Y, Bennett MJ, et al. Fetal genotypes and pregnancy outcomes in 35 families with mitochondrial trifunctional protein mutations. Am J Obstet Gynecol 2002; 187:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/21\">",
"      Mansouri A, Fromenty B, Durand R, et al. Assessment of the prevalence of genetic metabolic defects in acute fatty liver of pregnancy (letter). J Hepatol (Denmark) 1996; 25:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/22\">",
"      Bacq Y, Assor P, Gendrot C, et al. [Recurrent acute fatty liver of pregnancy]. Gastroenterol Clin Biol 2007; 31:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/23\">",
"      Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999; 340:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/24\">",
"      Jackson S, Kler RS, Bartlett K, et al. Combined enzyme defect of mitochondrial fatty acid oxidation. J Clin Invest 1992; 90:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/25\">",
"      Isaacs JD Jr, Sims HF, Powell CK, et al. Maternal acute fatty liver of pregnancy associated with fetal trifunctional protein deficiency: molecular characterization of a novel maternal mutant allele. Pediatr Res 1996; 40:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/26\">",
"      Matern D, Hart P, Murtha AP, et al. Acute fatty liver of pregnancy associated with short-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 2001; 138:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/27\">",
"      Yang Z, Yamada J, Zhao Y, et al. Prospective screening for pediatric mitochondrial trifunctional protein defects in pregnancies complicated by liver disease. JAMA 2002; 288:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/28\">",
"      Bellig LL. Maternal acute fatty liver of pregnancy and the associated risk for long-chain 3-hydroxyacyl-coenzyme a dehydrogenase (LCHAD) deficiency in infants. Adv Neonatal Care 2004; 4:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/29\">",
"      Rajasri AG, Srestha R, Mitchell J. Acute fatty liver of pregnancy (AFLP)--an overview. J Obstet Gynaecol 2007; 27:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/30\">",
"      Ibdah JA. Acute fatty liver of pregnancy: an update on pathogenesis and clinical implications. World J Gastroenterol 2006; 12:7397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/31\">",
"      Barton JR, Sibai BM. Hepatic imaging in HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count). Am J Obstet Gynecol 1996; 174:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/32\">",
"      Castro MA, Ouzounian JG, Colletti PM, et al. Radiologic studies in acute fatty liver of pregnancy. A review of the literature and 19 new cases. J Reprod Med 1996; 41:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/33\">",
"      Campillo B, Bernuau J, Witz MO, et al. Ultrasonography in acute fatty liver of pregnancy. Ann Intern Med 1986; 105:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/34\">",
"      Bacq Y. Acute fatty liver of pregnancy. Semin Perinatol 1998; 22:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/35\">",
"      Riely CA, Latham PS, Romero R, Duffy TP. Acute fatty liver of pregnancy. A reassessment based on observations in nine patients. Ann Intern Med 1987; 106:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/36\">",
"      Rolfes DB, Ishak KG. Acute fatty liver of pregnancy: a clinicopathologic study of 35 cases. Hepatology 1985; 5:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/37\">",
"      Ockner SA, Brunt EM, Cohn SM, et al. Fulminant hepatic failure caused by acute fatty liver of pregnancy treated by orthotopic liver transplantation. Hepatology 1990; 11:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/38\">",
"      Amon E, Allen SR, Petrie RH, Belew JE. Acute fatty liver of pregnancy associated with preeclampsia: management of hepatic failure with postpartum liver transplantation. Am J Perinatol 1991; 8:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/39\">",
"      MacLean MA, Cameron AD, Cumming GP, et al. Recurrence of acute fatty liver of pregnancy. Br J Obstet Gynaecol 1994; 101:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/40\">",
"      Barton JR, Sibai BM, Mabie WC, Shanklin DR. Recurrent acute fatty liver of pregnancy. Am J Obstet Gynecol 1990; 163:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24166/abstract/41\">",
"      Visconti M, Manes G, Giannattasio F, Uomo G. Recurrence of acute fatty liver of pregnancy. J Clin Gastroenterol 1995; 21:243.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3619 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24166=[""].join("\n");
var outline_f23_38_24166=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H116577307\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT AND COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116577307\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112472687\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3619\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3619|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/15/15606\" title=\"picture 1\">",
"      Acute fatty liver oil red O",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3619|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/53/23387\" title=\"table 1\">",
"      ACG guidelines liver disease during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26198?source=related_link\">",
"      Approach to liver disease occurring during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_38_24167="Human leukocyte antigens (HLA): A roadmap";
var content_f23_38_24167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Human leukocyte antigens (HLA): A roadmap",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/38/24167/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24167/contributors\">",
"     Wendy Thomson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24167/contributors\">",
"     Soumya Raychaudhuri, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/38/24167/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24167/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/38/24167/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24167/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/38/24167/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human leukocyte antigen (HLA) system is synonymous with the human major histocompatibility complex (MHC). These terms describe a group of genes on chromosome six that encode a variety of cell surface markers, antigen-presenting molecules, and other proteins involved in immune function.",
"   </p>",
"   <p>",
"    The earliest HLA associations with rheumatic diseases, such as the association of the HLA-B*27 allele at the HLA-B gene with ankylosing spondylitis risk and the association of the HLA-DRB1*04 allele at the HLA-DRB1 gene with rheumatoid arthritis, were discovered several decades ago. As the study of HLA genetics has evolved and expanded, the nomenclature has been continually altered, posing challenges for those attempting to follow the science. However, knowledge concerning this genetic region has evolved sufficiently, so the overall nomenclature should be more stable in the future, even though new alleles will be identified and catalogued.",
"   </p>",
"   <p>",
"    The genetics, nomenclature, and typing of HLA, as well as the relationships between HLA and rheumatic disease, are discussed here. The older nomenclature that may still be encountered in the literature is defined. The specific function of the MHC system, including the mechanisms of antigen presentation, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETIC STRUCTURE OF THE HLA REGION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major histocompatibility complex (MHC) refers to a genetic region containing hundreds of genes, including the HLA (human leukocyte antigen) genes. Thus, the MHC is often also referred to as the HLA region. These HLA genes express their gene products on the surface of white blood cells and were originally recognized to contain the genes encoding &ldquo;tissue antigens&rdquo; or &ldquo;tissue types.&rdquo; The function of these genes was revealed in rodent studies, in which they were identified as the factors responsible for rejection of tissue grafts between unmatched individuals.",
"   </p>",
"   <p>",
"    The MHC region lies on the short arm of chromosome six at position 6p21.3. The classical MHC spans 3.6 megabases (Mb) and includes more than 200 genes, many of which are not known to be involved in immune function. The localization of genes relevant to the MHC outside the classical boundaries of this region and confirmation of extended linkage disequilibrium have since led to the proposal for an extended MHC (xMHC). This region spans 7.6 Mb and contains over 400 loci. The complete structure and gene map of the HLA region have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MHC ORGANIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HLA region has been subdivided into three regions: class I, class II, and class III. Each region contains numerous gene loci, including expressed genes, transcripts, and pseudogenes. Some HLA loci are highly polymorphic.",
"   </p>",
"   <p>",
"    A detailed description of the MHC, including a full list of all the genes in each region, can be found at:",
"    <a class=\"external\" href=\"file://www.sanger.ac.uk/HGP/Chr6/XMHC/index.shtml\">",
"     www.sanger.ac.uk/HGP/Chr6/XMHC/index.shtml",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A brief review is provided in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Class I region",
"    </span>",
"    &nbsp;&mdash;&nbsp;The class I region contains the genes encoding the &ldquo;classical&rdquo; class I HLA antigens, HLA-A, B, and C. Class I antigens are expressed on almost all cells of the body, except erythrocytes and trophoblasts, at varying density [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/3\">",
"     3",
"    </a>",
"    ]. The class I antigens are made up of a heavy chain (alpha chain), which combines non-covalently with the non-polymorphic light chain (beta chain), to form the final dimerized molecule. The class I alpha chains are coded for by genes within the MHC (eg, HLA-A, HLA-B), whereas the beta chain, beta-2 microglobulin, is encoded on chromosome 15, not in the MHC.",
"   </p>",
"   <p>",
"    The class I region also contains other HLA class I genes such as HLA-E, HLA-F and HLA-G; MHC class I polypeptide related (MIC) genes; and a variety of other genes, not all of which are immune related. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36201?source=see_link\">",
"     \"Immunology of the maternal-fetal interface\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Class II region",
"    </span>",
"    &nbsp;&mdash;&nbsp;The class II region contains the genes encoding the HLA class II molecules, HLA-DR, DQ, and DP. Class II antigens are constitutively expressed on B cells, dendritic cells, and monocytes and can be induced during inflammation on many other cell types that normally have little or no expression.",
"   </p>",
"   <p>",
"    As with the class I molecules, the class II molecules also consist of an alpha (heavy) and a beta (light) chain. However, genes within the MHC (eg, HLA-DRA and HLA-DRB) code for both chains.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The DQ and DP antigens each have polymorphic alpha and beta chains, which can dimerize in various combinations.",
"     </li>",
"     <li>",
"      In contrast, DR dimers all share an essentially invariant alpha chain, while the beta chain carries the extreme polymorphism characteristic of these antigens.",
"     </li>",
"     <li>",
"      To add further complexity, the number of DR genes can vary among individuals. In some cases, two DR molecules are expressed on a single haplotype. Both dimers utilize the same invariant DR alpha chain, but one uses the beta chain encoded by the DRB1 locus gene, and the other uses a beta chain encoded by the second DR locus, called DRB3, DRB4, DRB5, etc. Alleles at this latter locus are usually expressed at much lower levels on the cell surface.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with the class I region, the class II region also contains many other genes, several of which assist in the processing and presentation of antigen. The DMA and DMB genes, for example, lie within the class II region and have structural similarities to both class I and class II genes. Analysis of mutant cells lacking DM genes reveals that these genes are critical to the process of loading peptides into class II molecules in endosomal compartments within the cell; when this process is defective, the class II molecules cannot appropriately bind processed antigen, traffic to the cell surface, or present antigen for recognition to the immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the class I antigen processing and presentation system, two other sets of genes in the MHC class III region, which are not structurally related to class I or class II genes, have been shown to play a role. LMP2 and LMP7 encode components of a proteasome complex that degrades cytoplasmic proteins into peptides that are then capable of being bound to and presented by class I molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. These peptide fragments are then transported into the endoplasmic reticulum by products of the transporter associated with antigen processing (TAP) genes, TAP1 and TAP2, each of which exists in several allelic forms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Without functional TAP genes, antigenic peptides cannot reach the endoplasmic reticulum, in which they normally bind to class I molecules and subsequently move to the cell surface, again to present peptides for recognition by the immune system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Class III region",
"    </span>",
"    &nbsp;&mdash;&nbsp;The region in between class I and class II is known as the class III region. Although this region does not contain any of the HLA genes, it does contain many genes of importance in the immune response, a few examples of which are given below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Complement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several complement components (C2, C4, and factor B) are encoded in this region; diseases like systemic lupus erythematosus have been associated with particular null alleles at these loci, although the mechanism whereby they may be important is not understood [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Tumor necrosis factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cytokines known to play in role in various inflammatory pathways (tumor necrosis factor-alpha [TNF], lymphotoxin alpha, and lymphotoxin beta) are also encoded in the MHC. TNF polymorphisms have been associated with autoimmune diseases such as systemic lupus erythematosus, and TNF has been shown to play an important role in regulating the inflammation of rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Heat shock protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;A heat shock protein gene, HSP-70, encodes a chaperone molecule that may be relevant to the pathogenesis of rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance to normal and aberrant immune function of these and other genes in the MHC whose function is not yet understood is the subject of ongoing research.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     METHODS OF HLA TYPING AND CHANGING NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the technology used to genotype HLA genes has evolved over the years, the nomenclature for the different alleles at individual HLA genes has evolved. Originally, before the widespread availability of sequence-based approaches, genotyping was done by using immunological techniques to query the protein structures of the HLA gene products on cell surfaces. Different alleles code for different versions of the same protein, and immunological techniques are sensitive to some, but not all, of these differences. The original nomenclature used for different alleles referred to the specific immunological reagents used to type. As those alleles have been subdivided into different sets of alleles with gene sequencing methods, which can identify more subtle differences, the nomenclature has evolved.",
"   </p>",
"   <p>",
"    Thus, the nomenclature has been frequently revised as advances were made in understanding HLA polymorphism. As a result, the literature is full of variations that can be frustrating to the nonspecialist: how would one know that DRB1*1501 is a DR2 allele? A brief historical overview, using DR4 as an example, may make this clearer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16402732\">",
"    <span class=\"h2\">",
"     Immunological typing methods",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest typing was performed by serologic methods. Women are exposed to foreign, paternally-derived HLA antigens during pregnancy and can develop antibodies to these antigens. Sera from numerous multiparous women were screened for those reacting reproducibly to certain HLA types. The epitopes recognized by these sera were generally shared, or &ldquo;public,&rdquo; epitopes, which are present on a family of related alleles. Thus, a person would be labeled &ldquo;DR4&rdquo; if their cells reacted with sera characterized as seeing this epitope.",
"   </p>",
"   <p>",
"    The presence of a second DR specificity in some individuals was also recognized. Sera were characterized that recognized these less polymorphic specificities. Most individuals positive for DR4 were also positive for the second DR specificity, DRw53. Similarly, haplotypes carrying the DR3, DR5, or DR6 specificities were normally positive for DRw52, which later was split into DRw52a, DRw52b, etc, by more specific sera.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cellular typing",
"    </span>",
"    &nbsp;&mdash;&nbsp;It soon became clear that human T cells could distinguish more precise &ldquo;splits&rdquo; among some of the HLA specificities recognized by these sera. As a result, mixed lymphocyte typing was developed to allow more exact typing. A panel of reference cells was generated that were homozygous for different antigens, called homozygous typing cells (HTCs). Cells from an individual of unknown HLA type were tested for recognition by the panel cells. In this way, the DR4 &ldquo;type&rdquo; could be split into several subtypes, such as Dw4, Dw10, Dw14, etc.",
"   </p>",
"   <p>",
"    Since both the sera from multiparous women and, especially, the HTCs were continually in need of replenishment and replacement, international histocompatibility workshops, under the auspices of the World Health Organization, were held periodically to compare and share reagents from around the world in an attempt to ensure some consistency. When consensus was reached on a new antigenic specificity, it would be given a new number with the designation &ldquo;w&rdquo; for &ldquo;workshop.&rdquo; As a specificity became widely reproducible and accepted, the &ldquo;w&rdquo; would be dropped, and a &ldquo;permanent&rdquo; name would be given. Thus, in one workshop, a newly identified specificity might be given the name DRw4, and, in a few years, it might be revised to DR4. &ldquo;DR&rdquo; implies a serologically-based definition, and &ldquo;D&rdquo; means cellularly typed. In this way, one HLA specificity could be DR4,Dw4 or DR4,Dw10.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     DNA based typing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major developments occurred that have led to molecular-based HLA typing and that allowed a more stable nomenclature system to be developed. First, the gene structure and sequence for the HLA genes were determined, thus allowing the identification of the polymorphic regions of the genes (",
"    <a class=\"graphic graphic_figure graphicRef67233 \" href=\"UTD.htm?1/20/1359\">",
"     figure 1",
"    </a>",
"    ). Second, polymerase chain reaction (PCR) technology was developed. This procedure permits amplification of specific DNA fragments that are then sufficiently abundant for analysis. PCR technology has provided the basis for development of convenient and rapid methods of HLA typing, based upon the exact nucleotide sequences of individual alleles.",
"   </p>",
"   <p>",
"    Traditional DNA cloning and sequencing had been performed on some HLA genes prior to PCR, but this was difficult and time-consuming. With the advent of PCR, dozens of individuals were rapidly sequenced, and a surprising number of new polymorphisms were identified.",
"   </p>",
"   <p>",
"    Following are DR4 examples. Serological typing allowed HLA-DR4 individuals to be identified. Cellular typing showed that HLA-DR4 could be split into a number of specificities (eg, DR4Dw4 or DR4Dw14), and molecular typing has been able to split these still further. Thus, Dw4 was determined to have a sequence now called DRB1*0401, while Dw14 was found to include at least two alleles, called DRB1*0404 and *0408. Other alleles, such DRB1*0409, *0410, and *0411, had not previously been identified. Over 20 DR4 alleles are known, and more are being discovered, particularly as HLA genes of disparate ethnic groups are being analyzed. A more detailed description of the nomenclature system is available on the internet [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, full HLA class II typing begins with drawing a patient&rsquo;s blood and extracting DNA from the white blood cells. Rapid and simple methods have supplanted the original process of separating the white blood cells by density gradient centrifugation, lysing the cells, and precipitating the DNA. A number of PCR-based methods are available for determining which alleles are present. The most commonly used method for disease studies is sequence specific oligonucleotide probes (SSOP). In this technique, the DNA undergoes PCR amplification, using a set of carefully selected primers designed to amplify the desired portion of DNA, such as a part of the DRB1 gene. Different primer sets are used for different loci, such as DRB, DQA, DQB, etc. The amplified section of DNA is then probed with various SSOPs, which are typically labeled by nonradioactive means and which have been designed to bind only to specific sequences that discriminate among alleles. Due to the complexity and number of allelic sequences, a single SSOP rarely can identify a specific allele. Rather, a patchwork of reactivity to various probes is required for determination of the allele.",
"   </p>",
"   <p>",
"    DNA-based HLA typing is by no means trivial. However, the results reflect a precise determination of individual alleles and are not dependent upon the interpretation of variable biologic reagents. Furthermore, the reagents can all be synthesized and quality-controlled, the method lends itself to automation, and more and more laboratories are becoming familiar with the use of PCR technology. Commercially available automated or semi-automated HLA typing systems are utilized in many laboratories.",
"   </p>",
"   <p>",
"    In many cases, full HLA typing is not necessary, since one may want to know only if a disease-associated susceptibility allele is present in an individual. A semi-automated &ldquo;kit&rdquo; to detect the presence of rheumatoid arthritis susceptibility alleles, for example, has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23546?source=see_link\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16402746\">",
"    <span class=\"h3\">",
"     Next generation DNA based typing",
"    </span>",
"    &nbsp;&mdash;&nbsp;While highly accurate methods to type HLA genes based on DNA sequence remain expensive and time-consuming, there is every expectation that ongoing advances in DNA sequencing technologies will facilitate rapid and economical typing in the near future [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/16\">",
"     16",
"    </a>",
"    ]. Several investigators have devised preliminary approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. These technologies are still evolving and are not yet in widespread use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INTERPRETATION OF HLA AND DISEASE ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over one hundred diseases are associated with classical HLA I and II genes, as well as with some of the non-HLA genes in the MHC region (eg, C4 complement) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. More information on the contribution of genetic variation within the MHC to the pathogenesis of, to the risk of developing, and to the severity of specific diseases is discussed in topic reviews that discuss these aspects of the relevant disease. (See appropriate topics.) A more detailed discussion of genetic association studies and their interpretation is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=see_link\">",
"     \"Genetic association studies: Principles and applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is reasonable to ask whether these studies are relevant to clinical practice and why there are so many studies. Part of the confusion arises from the evolution of HLA typing methods as previously described. Many early studies used serologic typing methods, so the results might describe, for example, that rheumatoid arthritis (RA) was associated with DR4.",
"   </p>",
"   <p>",
"    However, DR4 encompasses many different alleles, some of which are RA-associated and some of which are not; as a result, the associations were generally weaker than when the precise alleles were subsequently investigated. Subsequent studies using DNA-based methods have consistently shown that, in Caucasians, the alleles DRB1*0401, *0404, *0405, and *0408 are highly associated with RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23546?source=see_link\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With ankylosing spondylitis, HLA-B27 is estimated to contribute only 16 to 50 percent of the total genetic risk. Of the 27 recognized alleles of HLA-B27, the strongest association with AS is with HLA-B*2705; among the Japanese and Chinese, it is with HLA-B*2704. There is less frequent association with the alleles HLA-B*2701, *2702, *2703, *2704, *2707, *2708, and *2710, and there is no association with *2706 and *2709. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One promising approach in understanding disease association has been the examination of variation at individual amino acid sites, as opposed to HLA alleles. In rheumatoid arthritis, for example, investigators were able to demonstrate that much of the association of HLA-DRB1 with rheumatoid arthritis is best explained by differences in the specific amino acid that occurs at position 11 in the DRB1 molecule encoded by the different HLA-DBR1 gene alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/21\">",
"     21",
"    </a>",
"    ]. Position 11 is located at the base of the DRB1 binding groove and probably modulates differential binding to key antigens involved in autoimmunity.",
"   </p>",
"   <p>",
"    Ethnic differences must also be taken into account. The frequency of a particular allele in one population can be very different from that in another population. As an example, DR4 was shown not to be associated with RA in Israeli Jews [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/22\">",
"     22",
"    </a>",
"    ]. However, RA-associated DR4 alleles are rarely present in this Israeli population. The most common DR4 allele is DRB1*0402, which is not disease-associated, thereby explaining the apparent paradox. For the same reason, the control group with which the patient group is compared must be ethnically matched for the results to be valid.",
"   </p>",
"   <p>",
"    Definition of the patient group is also responsible for some differences among studies. It now seems clear, for example, that the DRB1*0401, *0404, *0405, and *0408 alleles are associated with severe forms of RA. In studies of patient groups acquired from tertiary medical center practices, associations with these alleles are much stronger than in studies in which the patients come from primary care practices, presumably because of clinical differences in patient populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23546?source=see_link&amp;anchor=H2#H2\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\", section on 'HLA class II associations in rheumatoid arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Use of p values",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methods used to assess statistical significance are also critical. Most straightforward population studies of disease association use the chi-squared test to compare the frequency of a particular allele in the patient population with its frequency in a control population. If the p value is less than 0.05, the association is said to be statistically significant; this means that the chance of this association occurring by chance alone is less than 1 in 20.",
"   </p>",
"   <p>",
"    However, if one is analyzing dozens of different alleles for possible association, it becomes likely that one or more alleles will result in a spurious association in which p is less than 0.05 simply because of the many comparisons being made. As a result, the p value must be corrected for the number of tests performed. In other words, if one studies 10 different DR alleles for association with a particular disease, the p value for each one must be multiplied by 10. Thus, if the uncorrected p value is 0.05, the value becomes 0.5, or statistically nonsignificant, after correction. If, on the other hand, the original p value is 0.0005, the corrected value of p = 0.005 is still significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Linkage disequilibrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;One must also keep in mind the concept of linkage disequilibrium when interpreting association studies. As noted above, a set of alleles are often inherited together. For example, the ancestral 8.1 haplotype spans the MHC region and includes the *0101 allele at HLA-A, the *0701 at HLA-C, the *0801 allele at HLA-B, the *0301 at HLA-DRB1, the *0101 allele at HLA-DRB3, the *0501 allele at HLA-DQB1, and the *0201 allele at HLA-DQB1. As a result, all of the alleles can be seen together, and, in a genetic study, it can, therefore, be difficult to say which locus is primarily responsible for the association in such cases. An apparent association of a particular disease with, for example, DR3 might actually be due to an association with a linked gene, such as DQB1*0201, or even with a non-HLA gene such as a TNF polymorphism. While narcolepsy has been associated with HLA-DR2, the association is stronger with the haplotype",
"    <span class=\"nowrap\">",
"     DQA1*0102/DQB1*0602",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Relative risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finally, one must remember that these are population studies and that the results cannot be easily transferred to an individual patient. The alleles that have been shown to be associated with disease are susceptibility alleles and are identical to genes that are present among normal individuals, albeit with lower frequency. One can use the calculation of relative risk (RR) to indicate the odds that the disease will occur among individuals positive for the allele compared with individuals negative for the allele. The RR is calculated from the following formula:",
"   </p>",
"   <p>",
"    RR = (the number of patients positive for the allele divided by the number of controls positive for the allele) divided by (the number of patients negative for the allele divided by the number of controls negative for the allele)",
"   </p>",
"   <p>",
"    The RR for developing RA in Caucasians if one carries DRB1*0401, for example, is about 6.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     HOW DO HLA ANTIGENS CONFER DISEASE SUSCEPTIBILITY?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the relationship of HLA antigens to disease susceptibility remain at the level of associations, not disease mechanisms. Nevertheless, HLA associations that are reproducible and robust are giving us important clues about the development of certain rheumatic diseases. A variety of models have been postulated to explain these associations functionally. These include the importance of HLA polymorphisms in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Shaping the T cell repertoire during development",
"     </li>",
"     <li>",
"      Shaping the peripheral T cell repertoire",
"     </li>",
"     <li>",
"      Determining which antigenic peptides are bound and, therefore, are presented to the immune system for recognition",
"     </li>",
"     <li>",
"      Generating molecular mimicry between self antigens and either the HLA molecule itself or peptides that it recognizes",
"     </li>",
"     <li>",
"      Affecting HLA protein presentation of either foreign or self antigenic peptides to autoreactive T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Influencing how infection, exogenous agents, or &ldquo;molecular mimicry&rdquo; may reactivate silenced T cells in autoimmune diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Affecting immune suppression and cancer development in important ways through the loss of HLA gene expression because of viral infection, somatic mutations, or other causes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/38/24167/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Influencing antigen processing and presentation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Identifying the mechanistic basis of these disease associations should lead to novel and specific treatment and even to preventive strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75073771\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The human leukocyte antigen (HLA) system is synonymous with the human major histocompatibility complex (MHC). These terms describe a group of genes on chromosome six that encode a variety of cell surface markers, antigen-presenting molecules, and other proteins involved in immune function. The classical MHC spans 3.6 megabases (Mb) and includes more than 200 genes, many of which are not known to be involved in immune function. The identification of MHC-related genes outside these boundaries and findings of extended linkage disequilibrium have led to the proposal for an extended MHC, which spans 7.6 Mb and which contains over 400 loci. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetic structure of the HLA region'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The HLA region has been subdivided into three regions: class I, class II, and class III. Each region contains numerous gene loci, including expressed genes, transcripts, and pseudogenes. Some HLA loci are highly polymorphic. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'MHC organization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The class I region contains the genes encoding the class I HLA antigens, which include HLA A, B, and C. Class I antigens are expressed on almost all cells of the body, except erythrocytes and trophoblasts, at varying density. The class I antigens are made up of a heavy chain (alpha chain) encoded within the MHC, which combines non-covalently with the non-polymorphic light chain (beta chain), also termed &beta;2-microglobulin, which is encoded on chromosome 15, not in the MHC, to form the final dimerized molecule. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Class I region'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The class II region contains the genes encoding the HLA class II molecules, HLA-DR, DQ, and DP. Class II antigens are constitutively expressed on B cells, dendritic cells, and monocytes and can be induced during inflammation on many other cell types that normally have little or no expression. As with the class I molecules, the class II molecules also consist of an alpha (heavy) and a beta (light) chain. However, genes within the MHC (eg, HLA-DRA and HLA-DRB) code for both chains. The DQ and DP antigens each has polymorphic alpha and beta chains, which can dimerize in various combinations; in contrast, DR dimers all share an essentially invariant alpha chain, while the beta chain carries the extreme polymorphism characteristic of these antigens. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Class II region'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The region in between class I and class II is known as the class III region. Although this region does not contain any of the HLA genes, it does contain many genes of importance in the immune response, including several complement components (C2, C4, and factor B); several cytokines known to play a role in inflammatory pathways, such as tumor necrosis factor-alpha (TNF), lymphotoxin alpha, and lymphotoxin beta; and a heat shock protein gene, HSP-70, that encodes a chaperone molecule. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Class III region'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determination of HLA types has become much more accurate and has led to frequent revision of the nomenclature. Typing was initially performed by serologic methods, and then additional specificities were detected by mixed lymphocyte typing using homozygous typing cells. Two major developments that have led to molecular-based HLA typing and a more stable nomenclature have been the determination of the gene structure and sequence for the HLA genes and the development of polymerase chain reaction (PCR) technology. PCR has provided the basis for convenient and rapid HLA typing methods, based upon the exact nucleotide sequences of individual alleles. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Methods of HLA typing and changing nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many diseases are associated with classical HLA I and II genes, as well as with some of the non-HLA genes in the MHC region (eg, C4 complement). Results among different ethnicities may vary, and definition of the patient group may influence degrees of association. Attention should be given to the statistical methods used when interpreting association studies. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Interpretation of HLA and disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data regarding HLA antigens and disease remain at the level of associations, not disease mechanisms. Nevertheless, HLA associations that are reproducible and robust provide important clues about the development of certain disorders. A variety of models have been postulated to explain these associations functionally. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'How do HLA antigens confer disease susceptibility?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/1\">",
"      Shiina T, Inoko H, Kulski JK. An update of the HLA genomic region, locus information and disease associations: 2004. Tissue Antigens 2004; 64:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/2\">",
"      Horton R, Wilming L, Rand V, et al. Gene map of the extended human MHC. Nat Rev Genet 2004; 5:889.",
"     </a>",
"    </li>",
"    <li>",
"     Milford EL, Carpenter CB. Adapative immunity: Histocompatibility antigens and immune response genes. In: ACP Medicine, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/4\">",
"      Busch R, Mellins ED. Developing and shedding inhibitions: how MHC class II molecules reach maturity. Curr Opin Immunol 1996; 8:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/5\">",
"      Kelly A, Trowsdale J. Novel genes in the human major histocompatibility complex class-II region. Int Arch Allergy Immunol 1994; 103:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/6\">",
"      Belich MP, Trowsdale J. Proteasome and class I antigen processing and presentation. Mol Biol Rep 1995; 21:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/7\">",
"      Vandevyver C, Geusens P, Cassiman JJ, Raus J. Peptide transporter genes (TAP) polymorphisms and genetic susceptibility to rheumatoid arthritis. Br J Rheumatol 1995; 34:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/8\">",
"      Reveille JD. Molecular genetics of systemic lupus erythematosus and Sj&ouml;gren's syndrome. Curr Opin Rheumatol 1990; 2:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/9\">",
"      Christiansen FT, Zhang WJ, Griffiths M, et al. Major histocompatibility complex (MHC) complement deficiency, ancestral haplotypes and systemic lupus erythematosus (SLE): C4 deficiency explains some but not all of the influence of the MHC. J Rheumatol 1991; 18:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/10\">",
"      Jacob CO, Fronek Z, Lewis GD, et al. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A 1990; 87:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/11\">",
"      Tomita Y, Hashimoto S, Yamagami K, et al. Restriction fragment length polymorphism (RFLP) analysis in the TNF genes of patients with systemic lupus erythematosus (SLE). Clin Exp Rheumatol 1993; 11:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/12\">",
"      Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/13\">",
"      Auger I, Escola JM, Gorvel JP, Roudier J. HLA-DR4 and HLA-DR10 motifs that carry susceptibility to rheumatoid arthritis bind 70-kD heat shock proteins. Nat Med 1996; 2:306.",
"     </a>",
"    </li>",
"    <li>",
"     Anthony Nolan Trust www.anthonynolan.org.uk/research/hlainformaticsgroup/nomenclature.htm (Accessed on October 13, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/15\">",
"      Nepom GT, Gersuk V, Nepom BS. Prognostic implications of HLA genotyping in the early assessment of patients with rheumatoid arthritis. J Rheumatol Suppl 1996; 44:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/16\">",
"      Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/17\">",
"      Bentley G, Higuchi R, Hoglund B, et al. High-resolution, high-throughput HLA genotyping by next-generation sequencing. Tissue Antigens 2009; 74:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/18\">",
"      Iqbal Z, Caccamo M, Turner I, et al. De novo assembly and genotyping of variants using colored de Bruijn graphs. Nat Genet 2012; 44:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/19\">",
"      Holcomb CL, H&ouml;glund B, Anderson MW, et al. A multi-site study using high-resolution HLA genotyping by next generation sequencing. Tissue Antigens 2011; 77:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/20\">",
"      Erlich RL, Jia X, Anderson S, et al. Next-generation sequencing for HLA typing of class I loci. BMC Genomics 2011; 12:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/21\">",
"      Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24167/abstract/22\">",
"      Schiff B, Mizrachi Y, Orgad S, et al. Association of HLA-Aw31 and HLA-DR1 with adult rheumatoid arthritis. Ann Rheum Dis 1982; 41:403.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3987 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24167=[""].join("\n");
var outline_f23_38_24167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H75073771\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETIC STRUCTURE OF THE HLA REGION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MHC ORGANIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Class I region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Class II region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Class III region",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Complement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Tumor necrosis factor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Heat shock protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      METHODS OF HLA TYPING AND CHANGING NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16402732\">",
"      Immunological typing methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cellular typing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DNA based typing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16402746\">",
"      - Next generation DNA based typing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INTERPRETATION OF HLA AND DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Use of p values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Linkage disequilibrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Relative risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HOW DO HLA ANTIGENS CONFER DISEASE SUSCEPTIBILITY?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H75073771\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/3987\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/3987|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/20/1359\" title=\"figure 1\">",
"      DNA based HLA typing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=related_link\">",
"      Genetic association studies: Principles and applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23546?source=related_link\">",
"      HLA and other susceptibility genes in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36201?source=related_link\">",
"      Immunology of the maternal-fetal interface",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=related_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_38_24168="Normal thoracic aorta";
var content_f23_38_24168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F86026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F86026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Normal thoracic aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 645px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24168=[""].join("\n");
var outline_f23_38_24168=null;
var title_f23_38_24169="Tumor necrosis factor-alpha inhibitors and mycobacterial infections";
var content_f23_38_24169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/38/24169/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24169/contributors\">",
"     Robert S Wallis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/38/24169/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24169/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/38/24169/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24169/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/38/24169/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/38/24169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of tumor necrosis factor-alpha (TNF-alpha) represent important treatment advances in a number of inflammatory conditions, including rheumatoid arthritis, the seronegative spondyloarthropathies, and inflammatory bowel disease. TNF-alpha inhibitors offer a targeted strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most inflammatory diseases.",
"   </p>",
"   <p>",
"    However, multiple complications and adverse effects of targeted TNF-alpha inhibition have been identified. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mycobacterial infection, particularly tuberculosis",
"     </li>",
"     <li>",
"      Other infections (bacterial, viral, and fungal)",
"     </li>",
"     <li>",
"      Injection site reactions",
"     </li>",
"     <li>",
"      Infusion reactions",
"     </li>",
"     <li>",
"      Induction of autoimmunity",
"     </li>",
"     <li>",
"      Demyelinating disease",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The association between TNF-alpha inhibitor use and tuberculosis (TB) and nontuberculous mycobacterial infections will be reviewed here. Other major complications of TNF-alpha therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2120?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TNF-ALPHA INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several inhibitors of TNF-alpha have been approved for the treatment of a variety of inflammatory illnesses (eg, rheumatoid arthritis, Crohn's disease) by the United States Food and Drug Administration (FDA). These medications are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      &mdash; A chimeric",
"      <span class=\"nowrap\">",
"       (mouse/human)",
"      </span>",
"      anti-TNF-alpha monoclonal antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      &mdash; A fully human monoclonal anti-TNF-alpha antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      &mdash; A soluble TNF-alpha receptor fusion protein",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"       Certolizumab pegol",
"      </a>",
"      &mdash; A pegylated Fab fragment of a humanized monoclonal antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       Golimumab",
"      </a>",
"      &mdash; A human monoclonal anti-TNF-alpha antibody",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These agents are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TNF-ALPHA AND HOST DEFENSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of tumor necrosis factor-alpha (TNF-alpha) in protection against several mycobacterial infections, including Mycobacterium tuberculosis, M. avium, M. bovis, and Bacillus Calmette-Gu&eacute;rin (BCG), has been studied in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Mycobacteria are not killed readily by host defense mechanisms, but instead are sequestered within granulomas, which are comprised of a central core of macrophages, multinucleated giant cells, and necrotic debris surrounded by macrophages and lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/6\">",
"     6",
"    </a>",
"    ]. TNF-alpha is required for the orderly recruitment of these cells and for continued maintenance of the granuloma structure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link&amp;anchor=H4#H4\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'TNF-alpha and host defenses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK OF TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor necrosis factor-alpha (TNF-alpha) inhibitors increase the risk of reactivation of latent TB infection (LTBI) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/8-17\">",
"     8-17",
"    </a>",
"    ]. This risk is greater for the anti-TNF antibodies",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    than for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/8-11,16,18\">",
"     8-11,16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of TB reactivation from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    is uncertain as experience with this newer drug is limited. Several cases of TB were reported in clinical trials of certolizumab pegol for the treatment of rheumatoid arthritis, while no cases occurred in the control arms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of data on the risk of TB from TNF-alpha inhibitors comes from large registries, which have several limitations. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Study limitations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Selected studies are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     AERS database",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) is a database that was established for postmarketing surveillance of adverse drug events. Using this database from 1998 to 2002, investigators found that among patients in the United States treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , estimated rates of TB were 54 and 28 per 100,000 patients who started therapy during the study period, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. These rates are substantially higher than the overall rates of TB in the United States during the same period (5.2 to 6.8 cases per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study of the AERS database examined all reports of TB associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    between 1998 and 2001 worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/8\">",
"     8",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were 70 cases of TB after treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , 64 of which were from countries with a low incidence of TB.",
"     </li>",
"     <li>",
"      These cases occurred a median of 12 weeks after the first",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      infusion.",
"     </li>",
"     <li>",
"      Forty of the patients had extrapulmonary disease (17 had disseminated disease, 11 lymph node disease, 4 peritoneal disease, 2 pleural disease, and 1 each meningeal, enteric, paravertebral, bone, genital, and bladder disease).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later study of the AERS database of 130 patients who developed TB after receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    between 2001 and 2006 showed that additional risk factors for TB included the administration of other immunosuppressive drugs (in 89 patients), a history of latent or active TB (in 33 patients), and being born in or having spent extensive time in a TB-endemic region (in 25 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Spain and Portugal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies conducted in Spain and Portugal showed substantially higher rates of TB in patients receiving TNF-alpha inhibitors than did the United States Food and Drug Administration AERS database described above. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'AERS database'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The Spanish Society of Rheumatology Database on Biologic Products (BIOBADASER), an active surveillance project, was designed to assess the safety of TNF-alpha inhibitors in patients with rheumatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/9\">",
"     9",
"    </a>",
"    ]. Investigators compared the TB infection rate among 1540 patients who had received either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (86 percent) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (14 percent) to that of patients who had not received either agent. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were 17 cases of TB, all of which were among patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The calculated incidence of TB cases associated with the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      was approximately 1900 per 100,000 patients in the year 2000 and 1100 per 100,000 patients in 2001. By comparison, the baseline incidence in Spain in 2000 was 21 cases per 100,000 inhabitants.",
"     </li>",
"     <li>",
"      Extrapulmonary disease occurred in 11 of the 17 cases. Six patients developed disseminated or hepatosplenic disease, and five had disease involving the nervous system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In Portugal between 1999 and 2005, 13 cases of TB were reported in 960 patients (1.35 percent) exposed to TNF-alpha inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high TB case rates reported in registries in Spain and Portugal likely reflect the high incidence of latent TB infection in these countries compared with countries such as the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159703\">",
"    <span class=\"h2\">",
"     United Kingdom",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data collected through April 2008 from the British Society for Rheumatology Biologics Register, a national prospective observational study, were used to compare rates of TB in over 10,000 patients treated with a TNF-alpha inhibitor (3295 were receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , 3913 were receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , 3504 were receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ) and among 3232 patients with active rheumatoid arthritis receiving traditional disease-modifying antirheumatic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/18\">",
"     18",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were 40 cases of TB, all in the TNF-alpha cohort.",
"     </li>",
"     <li>",
"      The rate of TB was higher among patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      (144 events per 100,000 person-years) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (136 events per 100,000 person-years) compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      (39 events per 100,000 person-years).",
"     </li>",
"     <li>",
"      After adjustment, the incidence-rate ratio compared with patients who were receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      was 3.1 (95% CI 1.0-9.5) for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and 4.2 (95% CI 1.4-12.4) for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Twenty-five of 40 cases of TB (62 percent) were extrapulmonary; 11 cases involved disseminated disease.",
"     </li>",
"     <li>",
"      Patients of non-Caucasian ethnicity had a six-fold increased risk of TB than Caucasians.",
"     </li>",
"     <li>",
"      The median time to onset of disease was shortest for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      compared with the other TNF-alpha inhibitors. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Time to onset'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other studies from the United States, Germany, Sweden, the United Kingdom, and France have shown an increased risk of reactivation of TB in patients receiving TNF-alpha inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/11,14-16,18,23\">",
"     11,14-16,18,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Influence of underlying RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the studies cited above compared the incidence of TB in patients on TNF-alpha inhibitors with the baseline population risk. However, this may overestimate the absolute increase in risk since the majority of patients on these drugs have rheumatoid arthritis (RA), and RA itself has been associated with the development of TB in some [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/14,24\">",
"     14,24",
"    </a>",
"    ], though not all [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/23\">",
"     23",
"    </a>",
"    ], studies.",
"   </p>",
"   <p>",
"    Nevertheless, TNF-alpha inhibitors appear to increase the risk of TB beyond that which may be associated with RA itself. This was illustrated by hospitalization data from Sweden between 1999 and 2001 that assessed the relative risks of TB in patients with RA compared with the general population and of TB in patients with RA receiving TNF-alpha inhibitors compared with RA patients not treated with these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/14\">",
"     14",
"    </a>",
"    ]. The relative risk of TB among RA patients who were not treated with TNF-alpha inhibitors compared with the general population was 2.0 (95% CI 1.2-3.4). In contrast, the relative risk of RA patients treated with TNF-alpha inhibitors compared with RA patients not treated with TNF-alpha inhibitors was 4.0 (95% CI 1.3-12).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Study limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies to assess the impact of TNF-alpha inhibitors on the risk of tuberculosis and other mycobacterial infections face several potential obstacles. In most countries, TB rates are too low for significant numbers of cases to be captured in clinical trials. Instead, large non-randomized study designs are required, such as registries or voluntary reporting systems. Such study design may be subject to the confounding effects of incomplete reporting, as TB notification rates vary by country, and prescribing bias. As an example, in Europe, the countries with the highest and lowest incidence of TB differ by 100-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/25\">",
"     25",
"    </a>",
"    ]. This requires that cases and controls be carefully matched by country in order to make accurate estimates of TB risk from TNF-alpha inhibitors.",
"   </p>",
"   <p>",
"    Studies of reactivation of latent TB infection (LTBI) by TNF-alpha inhibitors are complicated by the absence of a gold standard test for latent TB infection. Current tests, such as the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST) and whole blood interferon-gamma release assays (IGRAs), may be falsely positive as they do not distinguish between persistence and immunologic memory in instances in which the infection has been eradicated by the host response [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/26\">",
"     26",
"    </a>",
"    ]. Conversely, the TST and IGRAs may be falsely negative in persons with immunosuppression and with inflammatory conditions. such as rheumatoid arthritis, either due to the underlying disease or its treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The standard method for distinguishing reactivation of latent infection from newly acquired infection is to perform DNA typing. If a given patient&rsquo;s isolate matches another patient&rsquo;s isolate that was isolated concurrently, then such clustering implies newly-acquired infection. These data are not available in large cohorts of patients with TB related to TNF-alpha inhibitors.",
"    <strong>",
"    </strong>",
"    However, cases of TB occurring among immunocompromised patients living in countries with a low incidence of TB are often associated with prior risk factors for TB, such as birth in a TB-endemic country. Thus, TB in this setting is often assumed to represent reactivation of LTBI, and is potentially preventable using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Latent TB infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RISK WITH DIFFERENT AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are important differences among the TNF-alpha inhibitors in the risk of TB reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/28\">",
"     28",
"    </a>",
"    ]. The risk of TB reactivation is higher with the monoclonal antibodies",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/8-13,16,18\">",
"     8-13,16,18",
"    </a>",
"    ];",
"    <span class=\"nowrap\">",
"     136-144/100,000",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     39/100,000",
"    </span>",
"    in a study from the UK [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Biological basis of differential risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several hypotheses to explain the higher risk of reactivation of latent TB infection (LTBI) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pharmacokinetic hypothesis attributes the excess risk of LTBI from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      to the high blood levels that occur shortly after intravenous infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/29\">",
"       29",
"      </a>",
"      ]. In contrast, blood levels of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      are low and vary little with dosing. However, the limited experience with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      appears to contradict this hypothesis, as it shares a pharmacokinetic profile with etanercept, but appears to have a TB risk similar to infliximab [",
"      <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/29-32\">",
"       29-32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibody-dependent mechanisms of the TNF-alpha antibodies may result in the death of TNF-alpha-expressing cells, thereby promoting reactivation of LTBI. The binding of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      to soluble trimeric TNF-alpha may result in the formation of large immune complexes, which may activate complement and cause cell lysis. However, there is no indication that cell death due to this mechanism occurs in vivo.",
"      <br/>",
"      <br/>",
"      Infliximab and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      have been reported to cause cell death due to apoptosis in lamina propria T cells in patients with Crohn's disease, both in vitro and in vivo [",
"      <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/33\">",
"       33",
"      </a>",
"      ]. This observation, which may predict clinical response, appears to be due to the ability of TNF-alpha antibodies to bind and cross-link membrane-associated TNF-alpha.",
"     </li>",
"     <li>",
"      T cell dysfunction without cell death was observed in whole blood cultures treated with TNF-alpha inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/34\">",
"       34",
"      </a>",
"      ]. In that study,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      reduced the proportion of TB-responsive CD4 cells by 70 and 50 percent, respectively, and suppressed antigen-induced interferon-gamma production by 65 to 70 percent. In contrast,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      had no significant effect on these parameters. Thus, the increased TB risk with infliximab and adalimumab may reflect their combined effects on TNF-alpha and interferon-gamma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TIME TO ONSET",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of TB that occur soon after the initiation of a TNF-alpha inhibitor are likely to represent reactivation of latent TB infection, whereas those that occur later may represent either delayed reactivation or newly acquired TB infection progressing directly to active disease (which would be expected to occur uniformly over time). Several studies have indicated shorter times to TB onset for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (range of median values: 12 to 32 weeks) compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (18 to 79 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/8,9,11-14,18,23\">",
"     8,9,11-14,18,23",
"    </a>",
"    ]. In a study from the UK evaluating all three drugs using the same methodology, the median time to event was lowest for infliximab (5.5 months) compared with etanercept (13.4 months) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    (18.5 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/18\">",
"     18",
"    </a>",
"    ]. Thirteen of 40 cases occurred after discontinuing treatment. The basis for different times of onset is unknown, but delayed onset may reflect differential drug effects on reactivation risk, occurrence of new infection, or the waning effects of prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    therapy for prevention of reactivation.",
"   </p>",
"   <p>",
"    In another study, 43 percent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    -associated cases of TB occurred during the first 90 days of treatment, a pattern consistent with reactivation of latent infection. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    -associated TB cases were distributed evenly throughout during the reporting period, with only 10 percent occurring during the first 90 days of treatment (",
"    <a class=\"graphic graphic_figure graphicRef70906 \" href=\"UTD.htm?9/20/9550\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk of TB'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LATENT INFECTION VERSUS NEW INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is assumed that most cases of TB in patients on TNF-alpha inhibitors, as with other forms of immune suppression, are due to reactivation of latent infection and are therefore preventable with treatment for latent TB infection (LTBI). However, patients living in TB-endemic regions or with other high-risk exposure (eg, active TB in the household) could also be at increased risk of newly acquired infection, which would only be prevented during the period of treatment of LTBI. In addition, in a study that used mathematical modeling, it was suggested that some of the increased risk of TB in individuals in non-TB-endemic regions, such as most of the United States and Europe, may be due to new infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/35\">",
"     35",
"    </a>",
"    ]. This hypothesis will require confirmation in prospective studies using DNA typing.",
"   </p>",
"   <p>",
"    Our understanding of the incidence of new TB infection due to TNF-alpha blockade is limited to isolated case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/30\">",
"     30",
"    </a>",
"    ]. As a result, efforts at prevention focus solely on identification and treatment of LTBI. If a greater role for newly acquired infection is confirmed by clinical studies, other strategies for prevention in regions of high TB transmission may be required. As more patients undergo tuberculin skin testing or interferon-gamma release assay testing and are treated for LTBI, it is possible that the difference in TB rates between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    will be reduced in regions with high TB prevalence, and that the time to TB onset following infliximab will increase. The most recent published analysis of the AERS database may support this concept [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'AERS database'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Latent TB infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;TB occurring in association with TNF-alpha inhibitors has a higher likelihood of involving extrapulmonary sites and of being disseminated at presentation compared with other TB cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/28,31,34,36\">",
"     28,31,34,36",
"    </a>",
"    ]. Patients with disseminated TB may lack pulmonary symptoms, leading to delays in diagnosis. Patients should be educated on the pulmonary and extrapulmonary symptoms of TB, including cough, fever, malaise, weight loss, night sweats, and enlarged lymph nodes. Patients with symptoms of potential TB should undergo diagnostic testing without delay. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk of TB'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A paradoxical worsening of symptoms in patients with reactivation of latent TB infection occurs in some patients after the discontinuation of the TNF-alpha inhibitors. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Disease worsening during TB treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SCREENING AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the risk of reactivation of latent TB infection (LTBI) in patients receiving TNF-alpha inhibitors, it is crucial to screen all patients for LTBI prior to starting a TNF-alpha inhibitor. Screening is recommended by the United States Centers for Disease Control and Prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients with evidence of LTBI should initiate LTBI therapy prior to starting a TNF-alpha inhibitor. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Latent TB infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Appropriate screening includes a full medical history, physical examination,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST) or interferon-gamma release assay (IGRA), and a chest radiograph in those with a positive TST or IGRA or a history or physical exam suggestive of TB [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/7,31,37,38\">",
"     7,31,37,38",
"    </a>",
"    ]. Although routine testing with both TST and IGRA is not recommended, it is reasonable under certain circumstances, which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link&amp;anchor=H365757216#H365757216\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\", section on 'United States guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434002566\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of screening was demonstrated in the Spanish registry of patients with rheumatic disease treated with TNF-alpha inhibitors, BIOBADASER, which investigated the impact of mandated recommendations implemented in 2002 regarding screening for and treatment of LTBI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/39\">",
"     39",
"    </a>",
"    ]. They noted a 74 percent reduction in TB case rates following the introduction of screening and treatment in patients with rheumatoid arthritis treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    . However, the remaining risk still appeared to be higher than that of the general population. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Spain and Portugal'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The benefit of screening has also been suggested by an observational study in the United States, a region that has substantially lower TB prevalence than Spain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434002573\">",
"    <span class=\"h2\">",
"     Screening following BCG administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals born in countries with high TB prevalence may have been vaccinated with Bacillus Calmette-Gu&eacute;rin (BCG) during childhood. BCG vaccination provides only partial protection against TB but may result in TST reactivity (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40136?source=see_link\">",
"     \"BCG vaccination\"",
"    </a>",
"    ). The interferon-gamma release assay (IGRA) can be helpful in the evaluation of BCG-vaccinated TST positive patients, although rates of indeterminate IGRA results are higher in patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/36,40,41\">",
"     36,40,41",
"    </a>",
"    ]. In individuals who are not at high risk of LTBI, and especially in such persons who have a history of BCG immunization, the IGRA may be useful for helping to distinguish a true positive TST from a false positive TST [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/38\">",
"     38",
"    </a>",
"    ]. However, in those with a higher risk of LTBI or higher risk of progression from LTBI to active disease (eg, TNF-alpha inhibitor therapy), a positive TST and negative IGRA may or may not reflect a false positive TST, and should be interpreted with caution in making decisions about the need for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    preventive therapy. In other words, the clinician should have a low threshold for treating such patients for LTBI given the increased risk of reactivation of LTBI in patients receiving TNF-alpha inhibitors. We therefore favor treatment for LTBI in all patients who require a TNF-alpha inhibitor who have either a positive TST or a positive IGRA.",
"   </p>",
"   <p>",
"    The evaluation for LTBI in patients who have received BCG is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\", section on 'False positive tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention recommends treatment of LTBI prior to starting a TNF-alpha inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, when active TB infection is diagnosed in a patient receiving a TNF-alpha inhibitor, this agent should be discontinued and treatment for active TB should be initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Latent TB infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention recommends treatment of LTBI for all patients planning to take a TNF-alpha inhibitor who have a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST) result of &ge;5 mm induration or a positive interferon-gamma release assay (IGRA) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/31\">",
"     31",
"    </a>",
"    ]. TNF-alpha inhibitor candidates with a negative TST (&lt;5 mm) or IGRA should also be treated for LTBI if there is evidence of remote TB disease on chest radiography (eg, regional fibrosis with or without hilar lymphadenopathy) or if there is epidemiologic evidence of prior TB exposure (eg, having had close contact to a TB case, or having resided in a country of high TB incidence).",
"   </p>",
"   <p>",
"    TNF-alpha inhibitor candidates with an indication for LTBI treatment should generally receive standard therapy, which is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    for nine months. The duration of LTBI therapy prior to starting a TNF-alpha inhibitor has not been established, but most authorities suggest that patients receive at least one month of LTBI treatment before starting anti-TNF-alpha therapy whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/7,42\">",
"     7,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\", section on 'Selecting a regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of LTBI will not protect against TB due to newly acquired infection, except perhaps during the time that treatment is administered. Thus, patients taking TNF-alpha inhibitors should avoid TB exposures (eg, occupational exposures such as health-care facilities with high TB prevalence, homeless shelters, prisons; travel to high TB prevalence regions). Treatment of LTBI with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    also will not protect against reactivation of infection due to isoniazid-resistant strains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Active TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;When active TB infection is diagnosed in a patient receiving a TNF-alpha inhibitor, treatment for active TB should be initiated without delay. Most authorities recommend that anti-TNF-alpha therapy be discontinued, at least temporarily. The optimal timing of reinitiation of a TNF-alpha inhibitor in patients with active TB remains to be determined. Some authorities suggest that TNF-alpha inhibitor treatment may be resumed after drug susceptibility results are known and clinical improvement is evident [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/31,43\">",
"     31,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small phase I trial of 16 HIV-positive patients with pulmonary TB who were started on adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    on day four of antituberculous therapy suggests that it is safe to use etanercept in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/44\">",
"     44",
"    </a>",
"    ]. However, this study involved a different patient population than those who typically require TNF-alpha inhibitor therapy. Further prospective studies are required before TNF-alpha inhibitors can be recommended routinely during the early phase of antituberculous therapy.",
"   </p>",
"   <p>",
"    The treatment of active TB is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Disease worsening during TB treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuation of a TNF-alpha inhibitor in the setting of active TB may be associated with a paradoxical worsening of TB [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/30,45,46\">",
"     30,45,46",
"    </a>",
"    ]. The basis for this is hypothesized to be an immune reconstitution inflammatory syndrome (IRIS). In such cases, the use of glucocorticoids may be beneficial. Some have suggested that the resumption of TNF-alpha inhibitors may be indicated, but this remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RISK OF NONTUBERCULOUS MYCOBACTERIAL INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the TNF-alpha inhibitors are thought to confer a greater risk of TB than of nontuberculous mycobacterial (NTM) infections, a 2007 survey of Infectious Diseases Society of America members of the Emerging Infections Network suggested that NTM infections were more likely than TB in patients receiving these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/47\">",
"     47",
"    </a>",
"    ]. Respondents were asked to report mycobacterial infections in their patients over the previous six months. In patients receiving biologic therapies, NTM infections were reported nearly twice as often as TB (32 versus 17 cases, respectively). Mycobacterium avium complex was the most frequently reported NTM species (in 16 patients), followed by M. chelonae (in 5 patients), M. abscessus (in 3 patients), M. marinum (in 3 patients), and others (in 5 patients).",
"   </p>",
"   <p>",
"    This survey contrasts with the results of the US Food and Drug Administration's MedWatch surveillance system, which has reported that TNF-alpha inhibitor-associated TB occurs 5 to 10 times more commonly than NTM and other granulomatous infections in patients receiving TNF-alpha inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/13\">",
"     13",
"    </a>",
"    ]. Since both of these reports are based on passive surveillance, the true relative proportion of NTM versus TB cases related to TNF-alpha inhibitor therapy in the US is unknown. Among other types of patients at risk for mycobacterial disease in the US, NTM infections are more common in US-born individuals, and TB is more common in those from TB-endemic countries. It is possible that the incidence of TB in patients treated with TNF-alpha blockers is now declining due to greater clinician awareness and more consistent screening and treatment of LTBI. Such screening is unlikely to affect NTM infections.",
"   </p>",
"   <p>",
"    Prospective studies will need to be done to establish the risk of NTM infection following TNF-alpha inhibitor use. If this risk is found to be substantially greater than is presently appreciated, preventive strategies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    may then need to be considered.",
"   </p>",
"   <p>",
"    The epidemiology of NTM infections in patients receiving TNF-alpha inhibitors was evaluated in a later review of the US MedWatch surveillance system, which included all cases reported through January 1, 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/38/24169/abstract/48\">",
"     48",
"    </a>",
"    ]. Of 239 cases reported, 105 (44 percent) met NTM disease criteria. Among those with NTM infections, the median age was 62 years, women predominated (65 percent), and most (70 percent) had rheumatoid arthritis. Most patients were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (65 percent) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (55 percent) in combination with a TNF-alpha inhibitor. M. avium was the most common species implicated, occurring in 50 percent of patients. A high rate of extrapulmonary disease was reported (44 percent), which included the skin and soft tissues (26 percent), bones or joints (9 percent), disseminated disease (8 percent), and the eye (1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor necrosis factor-alpha (TNF-alpha) inhibitors increase the risk of reactivation of latent M. tuberculosis infection (LTBI). This risk is greater with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk of TB'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk with different agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cases of TB occurring in association with TNF-alpha inhibitors have a higher likelihood of involving extrapulmonary sites and of being disseminated at presentation compared with other TB cases. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients treated with anti-TNF-alpha therapy should be educated on the pulmonary and extrapulmonary symptoms of TB. Patients with symptoms of potential TB should undergo diagnostic testing without delay. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with LTBI need treatment for this prior to initiating therapy with anti-TNF-alpha therapy. This requires screening for LTBI in all patients being considered for such therapy. Appropriate screening includes a full medical history, physical examination,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      (TST) or interferon-gamma release assay (IGRA), and a chest radiograph in those with a positive TST or a history or physical exam suggestive of TB. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Screening and prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with evidence of LTBI either by a TST &ge;5 mm (without regard to BCG status) or by IGRA be started on treatment for LTBI prior to initiating anti-TNF-alpha therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Latent TB infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with a negative TST (&lt;5 mm) or IGRA should also be started on treatment for LTBI prior to initiating anti-TNF-alpha therapy if there is evidence of remote TB disease on chest radiography (eg, regional fibrosis with or without hilar lymphadenopathy) or if there is epidemiologic evidence of prior TB exposure (eg, having had close contact to a TB case, or having resided in a country of high TB incidence) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that patients with LTBI be treated with anti-TB therapy for at least one month prior to starting anti-TNF-alpha therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Latent TB infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients diagnosed with LTBI who are planning to take TNF-alpha inhibitors should be treated with standard therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      for nine months. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Latent TB infection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"       \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that anti-TNF-alpha therapy be discontinued in patients who develop active TB at least until drug susceptibility can be ascertained (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients who require continued anti-TNF-alpha therapy, we suggest resuming anti-TNF-alpha therapy once the TB has improved on antituberculous treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Active TB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discontinuation of a TNF-alpha inhibitor in the setting of TB may be associated with a paradoxical worsening of TB, which is likely due to an immune reconstitution inflammatory syndrome. Patients with this reaction may benefit from glucocorticoids. Some have suggested that the resumption of TNF-alpha inhibitors may be indicated, but this remains controversial. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Disease worsening during TB treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TNF-alpha inhibitors may increase the risk of nontuberculous mycobacterial infections. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Risk of nontuberculous mycobacterial infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/1\">",
"      Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005; 41 Suppl 3:S189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/2\">",
"      Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/3\">",
"      Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/4\">",
"      Benini J, Ehlers EM, Ehlers S. Different types of pulmonary granuloma necrosis in immunocompetent vs. TNFRp55-gene-deficient mice aerogenically infected with highly virulent Mycobacterium avium. J Pathol 1999; 189:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/5\">",
"      Bopst M, Garcia I, Guler R, et al. Differential effects of TNF and LTalpha in the host defense against M. bovis BCG. Eur J Immunol 2001; 31:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/6\">",
"      Randhawa PS. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 1990; 22:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/7\">",
"      Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/8\">",
"      Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/9\">",
"      G&oacute;mez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/10\">",
"      Fonseca JE, Canh&atilde;o H, Silva C, et al. [Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience]. Acta Reumatol Port 2006; 31:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/11\">",
"      Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/12\">",
"      Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/13\">",
"      Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004; 39:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/14\">",
"      Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/15\">",
"      Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/16\">",
"      Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/17\">",
"      Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 72:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/18\">",
"      Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/19\">",
"      Keystone, E, Mason, D, Combe, B. The anti-TNF certolizumab pegol in combination with methotrexate is significantly more effective than methotrexate alone in the treatment of patients with active rheumatoid arthritis: preliminary results from the RAPID 1 study. Ann Rheum Dis 2007; 66(Suppl 2):55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/20\">",
"      Smolen, J, Brezezicki, J, Mason, D, Kavanaugh, A. Efficacy and safety of certolizumab pegol in combination with methotrexate (MTX) in patients with active rheumatoid arthritis despite MTX therapy: results from the RAPID 2 study. Ann Rheum Dis 2007; 66(Suppl 2):187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Trends in tuberculosis--United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2004; 53:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/22\">",
"      Raval A, Akhavan-Toyserkani G, Brinker A, Avigan M. Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007; 147:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/23\">",
"      Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/24\">",
"      Carmona L, Hern&aacute;ndez-Garc&iacute;a C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30:1436.",
"     </a>",
"    </li>",
"    <li>",
"     Global tuberculosis control - surveillance, planning, financing. Geneva Switzerland: World Health Organization; 2007. Report No. WHO/HTM/TB/2007.376. file://www.who.int/tb/publications/global_report/2007/en/index.html (Accessed on May 02, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/26\">",
"      Nardell EA, Wallis RS. Here today--gone tomorrow: the case for transient acute tuberculosis infection. Am J Respir Crit Care Med 2006; 174:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/27\">",
"      Coaccioli S, Di Cato L, Marioli D, et al. Impaired cutaneous cell-mediated immunity in newly diagnosed rheumatoid arthritis. Panminerva Med 2000; 42:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/28\">",
"      Mohan AK, Cot&eacute; TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/29\">",
"      Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 2005; 34:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/30\">",
"      Arend SM, Leyten EM, Franken WP, et al. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007; 45:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/32\">",
"      Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005; 41:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/33\">",
"      Ringheanu M, Daum F, Markowitz J, et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis 2004; 10:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/34\">",
"      Saliu OY, Sofer C, Stein DS, et al. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006; 194:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/35\">",
"      Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008; 58:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/36\">",
"      Hill PC, Brookes RH, Fox A, et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004; 38:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/37\">",
"      Hamilton CD. Tuberculosis in the cytokine era: what rheumatologists need to know. Arthritis Rheum 2003; 48:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/38\">",
"      Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/39\">",
"      Carmona L, G&oacute;mez-Reino JJ, Rodr&iacute;guez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/40\">",
"      Greenberg JD, Reddy SM, Schloss SG, et al. Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 2008; 35:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/41\">",
"      Brock I, Weldingh K, Lillebaek T, et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 170:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/42\">",
"      Furst DE, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008; 67 Suppl 3:iii2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/43\">",
"      Matsumoto T, Tanaka T, Kawase I. Infliximab for rheumatoid arthritis in a patient with tuberculosis. N Engl J Med 2006; 355:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/44\">",
"      Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/45\">",
"      Garcia Vidal C, Rodr&iacute;guez Fern&aacute;ndez S, Mart&iacute;nez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005; 40:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/46\">",
"      Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009; 48:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/47\">",
"      Winthrop KL, Yamashita S, Beekmann SE, et al. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008; 46:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/38/24169/abstract/48\">",
"      Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009; 15:1556.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1411 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24169=[""].join("\n");
var outline_f23_38_24169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TNF-ALPHA INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TNF-ALPHA AND HOST DEFENSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK OF TB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AERS database",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Spain and Portugal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1159703\">",
"      United Kingdom",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Influence of underlying RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Study limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RISK WITH DIFFERENT AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Biological basis of differential risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TIME TO ONSET",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LATENT INFECTION VERSUS NEW INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SCREENING AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H434002566\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H434002573\">",
"      Screening following BCG administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Latent TB infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Active TB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Disease worsening during TB treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RISK OF NONTUBERCULOUS MYCOBACTERIAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1411\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1411|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/20/9550\" title=\"figure 1\">",
"      TNF-alpha inhibitors and TB",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40136?source=related_link\">",
"      BCG vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2120?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_38_24170="Methotrexate: Drug information";
var content_f23_38_24170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methotrexate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"    see \"Methotrexate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"    see \"Methotrexate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rheumatrex&reg;;",
"     </li>",
"     <li>",
"      Trexall&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Methotrexate&reg;;",
"     </li>",
"     <li>",
"      ratio-Methotrexate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Antifolate);",
"     </li>",
"     <li>",
"      Antirheumatic, Disease Modifying;",
"     </li>",
"     <li>",
"      Immunosuppressant Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses between 100-500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     <b>",
"      may require",
"     </b>",
"     leucovorin calcium rescue. Doses &gt;500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     <b>",
"      require",
"     </b>",
"     leucovorin calcium rescue: I.V., I.M., Oral: Leucovorin calcium 10-15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 6 hours for 8 or 10 doses, starting 24 hours after the start of methotrexate infusion. Continue until the methotrexate level is &le;0.1 micromolar (10",
"     <sup>",
"      -7",
"     </sup>",
"     M). Some clinicians continue leucovorin calcium until the methotrexate level is &lt;0.05 micromolar (5 x 10",
"     <sup>",
"      -8",
"     </sup>",
"     M) or 0.01 micromolar (10",
"     <sup>",
"      -8",
"     </sup>",
"     M).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If the 48-hour methotrexate level is &gt;1 micromolar (10",
"     <sup>",
"      -6",
"     </sup>",
"     M) or the 72-hour methotrexate level is &gt;0.2 micromolar (2 x 10",
"     <sup>",
"      -7",
"     </sup>",
"     M): I.V., I.M, Oral: Leucovorin calcium 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 6 hours until the methotrexate level is &le;0.1 micromolar (10",
"     <sup>",
"      -7",
"     </sup>",
"     M). Some clinicians continue leucovorin calcium until the methotrexate level is &lt;0.05 micromolar (5 x 10",
"     <sup>",
"      -8",
"     </sup>",
"     M) or 0.01 micromolar (10",
"     <sup>",
"      -8",
"     </sup>",
"     M).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Antineoplastic dosage range:",
"     </b>",
"     I.V.: Range is wide from 30-40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week to 100-12,000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     with leucovorin calcium rescue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer:",
"     </b>",
"     I.V.: 30-60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     Day 1 and 8 every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Head and neck cancer:",
"     </b>",
"     Oral, I.M., I.V.: 25-50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lymphoma, non-Hodgkin's:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 3 and 10 every 3 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     day 8 and 15 every 3-4 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     day 8 and 15 every 3 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks for 3 cycles",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningeal leukemia:",
"     </b>",
"     I.T.: Usual dose: 12 mg/dose.",
"     <b>",
"      Note:",
"     </b>",
"     Optimal intrathecal chemotherapy dosing should be based on age rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (Bleyer, 1983; Kerr, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mycosis fungoides (cutaneous T-cell lymphoma):",
"     </b>",
"     Oral, I.M.: Initial (early stages):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-50 mg once weekly",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-37.5 mg twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteosarcoma:",
"     </b>",
"     I.V.: 8-12 g/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly for 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psoriasis:",
"     </b>",
"     Some experts recommend concomitant folic acid 1-5 mg/day (except the day of methotrexate) to reduce hematologic, gastrointestinal, and hepatic adverse events related to methotrexate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 2.5-5 mg/dose every 12 hours for 3 doses given weekly",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, I.M., SubQ: 10-25 mg/dose given once weekly; titrate to lowest effective dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     An initial test dose of 2.5-5 mg is recommended in patients with risk factors for hematologic toxicity or renal impairment. (Kalb, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Some experts recommend concomitant folic acid at a dose of least 5 mg/week (except the day of methotrexate) to reduce hematologic, gastrointestinal, and hepatic adverse events related to methotrexate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral (manufacturer labeling): 7.5 mg once weekly or 2.5 mg every 12 hours for 3 doses/week (dosage exceeding 20 mg/week may cause a higher incidence and severity of adverse events);",
"     <i>",
"      alternatively,",
"     </i>",
"     10-15 mg once weekly, increased by 5 mg every 2-4 weeks to a maximum of 20-30 mg once weekly has been recommended by some experts (Visser, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., SubQ (unlabeled route): 15 mg once weekly (dosage varies, similar to oral) (Braun, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Trophoblastic neoplasms:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, I.M.: 15-30 mg/day for 5 days; repeat in 7 days for 3-5 courses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 11 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 through 5 every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Unlabeled uses:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bladder cancer (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     day 1 and 8 every 3 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     day 1, 15, and 22 every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Crohn&rsquo;s disease, mild/moderate, corticosteroid-dependent or refractory (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remission induction or reduction of steroid use: I.M., SubQ: 25 mg once weekly (Lichtenstein, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remission maintenance: I.M.: 15 mg once weekly (Feagan, 2000; Lichtenstein, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dermatomyositis/polymyositis (unlabeled uses):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 7.5-15 mg/week, often adjunctively with high-dose corticosteroid therapy; may increase in weekly 2.5 mg increments to target dose of 10-25 mg/week (",
"     <b>",
"      Note:",
"     </b>",
"     Administration of folate 5-7 mg/week has been used to reduce side effects) (Briemberg, 2003; Newman, 1995; Wiendl, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V., I.M.: Doses of 20-60 mg/week have been employed if failure with oral therapy (doses &gt;50 mg/week may require leucovorin calcium rescue) (Briemberg, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ectopic pregnancy (unlabeled use):",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Single-dose regimen:",
"     </i>",
"     Methotrexate 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1; Measure serum hCG levels on days 4 and 7; if needed, repeat dose on day 7 (Barnhart, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Two-dose regimen:",
"     </i>",
"     Methotrexate 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1; Measure serum hCG levels on day 4 and administer a second dose of methotrexate 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; Measure serum hCG levels on day 7 and if needed, administer a third dose of 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (Barnhart, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Multidose regimen:",
"     </i>",
"     Methotrexate 1 mg/kg on day 1; leucovorin calcium 0.1 mg/kg I.M. on day 2; measure serum hCG on day 2; methotrexate 1 mg/kg on day 3; leucovorin calcium 0.1 mg/kg on day 4; measure serum hCG on day 4; continue up to a total of 4 courses based on hCG concentrations (Barnhart, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      GVHD (acute) prophylaxis:",
"     </b>",
"     I.V.: 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on day 1 and 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on days 3 and 6 after allogeneic transplant (in combination with cyclosporine and prednisone) (Chao, 1993; Chao, 2000; Ross, 1999)",
"     <b>",
"      or",
"     </b>",
"     15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on day 1 and 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on days 3, 6, and 11 after allogeneic transplant (in combination with cyclosporine) (Chao, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonleukemic meningeal cancer (unlabeled uses):",
"     </b>",
"     I.T.: 10-12 mg/dose twice weekly for 4 weeks, then weekly for 4 weeks, then monthly (NCCN CNS cancer guidelines v.2.2009)",
"     <b>",
"      or",
"     </b>",
"     12 mg/dose twice weekly for 4 weeks, then weekly for 4 doses, then monthly for 4 doses (Glantz, 1998)",
"     <b>",
"      or",
"     </b>",
"     10 mg twice weekly for 4 weeks, then weekly for 1 month, then every 2 weeks for 2 months (Glantz, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Takayasu arteritis, refractory or relapsing disease (unlabeled use):",
"     </b>",
"     Oral: Initial dose: 0.3 mg/kg/week (maximum: 15 mg/week), titrated by 2.5 mg increments every 1-2 weeks until reaching a maximum tolerated weekly dose of 25 mg (use in combination with a corticosteroid; Hoffman, 1994)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F194583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"      see \"Methotrexate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses between 100-500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     <b>",
"      may require",
"     </b>",
"     leucovorin calcium rescue. Doses &gt;500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     <b>",
"      require",
"     </b>",
"     leucovorin calcium rescue: I.V., I.M., Oral: Leucovorin calcium 10-15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 6 hours for 8 or 10 doses, starting 24 hours after the start of methotrexate infusion. Continue until the methotrexate level is &le;0.1 micromolar (10",
"     <sup>",
"      -7",
"     </sup>",
"     M). Some clinicians continue leucovorin calcium until the methotrexate level is &lt;0.05 micromolar (5 x 10",
"     <sup>",
"      -8",
"     </sup>",
"     M) or 0.01 micromolar (10",
"     <sup>",
"      -8",
"     </sup>",
"     M).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If the 48-hour methotrexate level is &gt;1 micromolar (10",
"     <sup>",
"      -6",
"     </sup>",
"     M) or the 72-hour methotrexate level is &gt;0.2 micromolar (2 x 10",
"     <sup>",
"      -7",
"     </sup>",
"     M): I.V., I.M, Oral: Leucovorin calcium 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 6 hours until the methotrexate level is &le;0.1 micromolar (10",
"     <sup>",
"      -7",
"     </sup>",
"     M). Some clinicians continue leucovorin calcium until the methotrexate level is &lt;0.05 micromolar (5 x 10",
"     <sup>",
"      -8",
"     </sup>",
"     M) or 0.01 micromolar (10",
"     <sup>",
"      -8",
"     </sup>",
"     M).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dermatomyositis (unlabeled use):",
"     </b>",
"     Oral: 15-20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week as a single dose once weekly",
"     <b>",
"      or",
"     </b>",
"     0.3-1 mg/kg/dose once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      GVHD (acute) prophylaxis (unlabeled use):",
"     </b>",
"     I.V.: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Juvenile idiopathic arthritis (JIA):",
"     </b>",
"     Oral, I.M.:10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly, then 5-15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week as a single dose",
"     <b>",
"      or",
"     </b>",
"     as 3 divided doses given 12 hours apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antineoplastic dosage range:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, I.M.: 7.5-30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week",
"     <b>",
"      or",
"     </b>",
"     every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 10-18,000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     bolus dosing",
"     <b>",
"      or",
"     </b>",
"     continuous infusion over 6-42 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pediatric solid tumors (high-dose):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;12 years: 12-25 g/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;12 years: 8 g/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute lymphocytic leukemia (intermediate-dose):",
"     </b>",
"     I.V.: Loading: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     bolus dose, followed by 900 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day infusion over 23-41 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningeal leukemia:",
"     </b>",
"     I.T.: 6-12 mg/dose based on age.",
"     <b>",
"      Note",
"     </b>",
"     : Optimal intrathecal chemotherapy dosing should be based on age rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (Bleyer, 1983; Kerr, 2001):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1 year: 6 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 year: 8 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 years: 10 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;3 years: 12 mg/dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F194561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols; adjust for renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Meningeal leukemia:",
"     </b>",
"     I.T.: Consider a dose reduction (CSF volume and turnover may decrease with age)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis/psoriasis:",
"     </b>",
"     Oral: Initial: 5-7.5 mg/week, not to exceed 20 mg/week",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F194562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling. The following adjustments have been recommended:",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Aronoff, 2007:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 30% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis: Administer 30% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer 30% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Kintzel, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 65% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 50% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F194563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; use with caution. The following adjustments have been recommended (Floyd, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bilirubin 3.1-5 mg/dL",
"     <b>",
"      or",
"     </b>",
"     transaminases &gt;3 times ULN: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bilirubin &gt;5 mg/dL: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15255058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonhematologic toxicity: Diarrhea, stomatitis, or vomiting which may lead to dehydration: Discontinue until recovery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic toxicity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Psoriasis, rheumatoid arthritis: Significant blood count decrease: Discontinue immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oncologic uses: Profound granulocytopenia and fever: Evaluate immediately; consider broad-spectrum parenteral antimicrobial coverage",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 25 mg/mL (2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 25 mg/mL (2 mL, 4 mL, 8 mL, 10 mL, 40 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trexall&trade;: 5 mg, 7.5 mg, 10 mg, 15 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [dose-pack]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rheumatrex&reg;: 2.5 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F194531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methotrexate may be administered I.M., I.V., intrathecally, or SubQ; I.V. administration may be as slow push, short bolus infusion, or 24- to 42-hour continuous infusion",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Specific dosing schemes vary, but high dose should be followed by leucovorin calcium to prevent toxicity; refer to Leucovorin Calcium monograph",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F194608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, asparaginase, aztreonam, bleomycin, cefepime, ceftriaxone, cimetidine, cisplatin, cyclophosphamide, cytarabine, daunorubicin HCl, diphenhydramine, doripenem, doxorubicin HCl, doxorubicin liposome, etoposide, etoposide phosphate, famotidine, filgrastim, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, granisetron, heparin, hydrocortisone sodium succinate, hydromorphone, imipenem/cilastatin, leucovorin calcium, linezolid, lorazepam, melphalan, mesna, methylprednisolone sodium succinate, metoclopramide, mitomycin, morphine, ondansetron, oxacillin, oxaliplatin, paclitaxel, piperacillin/tazobactam, prochlorperazine edisylate, ranitidine, sargramostim, teniposide, thiotepa, vinblastine, vincristine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Chlorpromazine, gemcitabine, idarubicin, ifosfamide, midazolam, nalbuphine, promethazine, propofol.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dexamethasone sodium phosphate, droperidol, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bleomycin, cisplatin, cyclophosphamide, cytarabine, doxapram, doxorubicin HCl, fluorouracil, furosemide, heparin sodium, hydrocortisone sodium succinate, leucovorin calcium, mitomycin, vinblastine, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Droperidol.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Metoclopramide.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F194530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oncology-related uses: Acute lymphoblastic leukemia (ALL) maintenance treatment, ALL meningeal leukemia (prophylaxis and treatment); treatment of trophoblastic neoplasms (gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole), breast cancer, head and neck cancer (epidermoid), cutaneous T-Cell lymphoma (advanced mycosis fungoides), lung cancer (squamous cell and small cell), advanced non-Hodgkin&rsquo;s lymphomas (NHL), osteosarcoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nononcology uses: Treatment of psoriasis (severe, recalcitrant, disabling) and severe rheumatoid arthritis (RA), including polyarticular-course juvenile idiopathic arthritis (JIA)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F854604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and maintenance of remission in Crohn&rsquo;s disease; management of ectopic pregnancy; dermatomyositis/polymyositis; treatment of bladder cancer, central nervous system tumors (including nonleukemic meningeal cancers), acute promyelocytic leukemia (maintenance treatment), soft tissue sarcoma (desmoid tumors); acute graft-versus-host disease (GVHD) prophylaxis; medical management of abortion; systemic lupus erythematosus; Takayasu arteritis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Methotrexate may be confused with mercaptopurine, methylPREDNISolone sodium succinate, metolazone, metroNIDAZOLE, mitoXANtrone, PRALAtrexate",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Errors have occurred (resulting in death) when methotrexate was administered as &ldquo;daily&rdquo; dose instead of the recommended &ldquo;weekly&rdquo; dose.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"       <i>",
"        Intrathecal medication safety:",
"       </i>",
"       The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson, 2009) encourage the following safety measures for intrathecal chemotherapy:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Intrathecal medication should not be prepared during the preparation of any other agents",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; After preparation, keep in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Delivery to the patient should only be with other medications also intended for administration into the central nervous system",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MTX is an error-prone abbreviation (mistaken as mitoxantrone)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Trexall [U.S.] may be confused with Trexol brand name for tamadol [Mexico]; Truxal brand name for chlorprothixene [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F194600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions vary by route and dosage. Hematologic and/or gastrointestinal toxicities may be common at dosages used in chemotherapy; these reactions are much less frequent when used at typical dosages for rheumatic diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system (with intrathecal administration or very high-dose therapy):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Arachnoiditis: Acute reaction manifested as severe headache, nuchal rigidity, vomiting, and fever; may be alleviated by reducing the dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Subacute toxicity: 10% of patients treated with 12-15 mg of intrathecal methotrexate may develop this in the second or third week of therapy; consists of motor paralysis of extremities, cranial nerve palsy, seizure, or coma. This has also been seen in pediatric cases receiving very high-dose I.V. methotrexate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Demyelinating encephalopathy: Seen months or years after receiving methotrexate; usually in association with cranial irradiation or other systemic chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Reddening of skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia, oligospermia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Ulcerative stomatitis, glossitis, gingivitis, nausea, vomiting, diarrhea, intestinal perforation, mucositis (dose dependent; appears in 3-7 days after therapy, resolving within 2 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia, myelosuppression (nadir: 7-10 days), thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal failure, azotemia, nephropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Immunosuppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, malaise, fever, chills",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, rash, photosensitivity, depigmentation or hyperpigmentation of skin, pruritus, dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Diabetes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cystitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cirrhosis (chronic therapy), liver function tests increased (chronic therapy), portal fibrosis (chronic therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal dysfunction: Manifested by an abrupt rise in serum creatinine and BUN and a fall in urine output; more common with high-dose methotrexate, and may be due to precipitation of the drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pneumonitis: Associated with fever, cough, and interstitial pulmonary infiltrates; treatment is to withhold methotrexate during the acute reaction; interstitial pneumonitis has been reported to occur with an incidence of 1% in patients with RA (dose 7.5-15 mg/week)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute neurologic syndrome (at high dosages; symptoms include confusion, hemiparesis, transient blindness, and coma); acute respiratory distress syndrome, agranulocytosis, alveolitis, anaphylaxis, arrhythmia, arterial occlusion (acute), arterial thrombosis, cerebral thrombosis, cerebrovascular accident, chronic leukoencephalopathy, cognitive dysfunction (has been reported at low dosage), cryptococcosis, cytomegalovirus infection (including cytomegaloviral pneumonia, sepsis, nocardiosis), deep vein thrombosis, disseminated vaccinia (following smallpox immunization), dysarthria, enteritis, eosinophilia, erythema multiforme, exfoliative dermatitis, GI bleeding, gynecomastia, hepatic failure, hepatitis, herpes simplex, herpes zoster, histoplasmosis, hypogammaglobulinemia, hypotension, impotence, infertility, intestinal perforation, leukoencephalopathy (especially following craniospinal irradiation or repeated high-dose therapy), lymphoma (may regress with discontinuation), lymphoproliferative disorders, mesenteric ischemia (acute), MI, myocardial ischemia, nasal septum perforation, neutropenia, nodulosis, osteoporosis, pancreatitis, pericardial effusion, osteonecrosis and soft tissue necrosis (with radiotherapy), pericarditis, plaque erosions (psoriasis),",
"     <i>",
"      Pneumocystis carinii",
"     </i>",
"     pneumonia, pneumonia, proteinuria, pulmonary embolism, pulmonary fibrosis, radiation recall dermatitis, respiratory failure, retinal vein thrombosis, reversible posterior leukoencephalopathy syndrome (RPLS), seizure (more frequent in pediatric patients with ALL), skin ulceration, Stevens-Johnson syndrome, stroke, supraventricular arrythmia, syncope, telangiectasia, thromboembolism, thrombophlebitis, toxic epidermal necrolysis, tumor lysis syndrome, upper respiratory tract infection, ventricular arrythmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F194534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methotrexate or any component of the formulation; breast-feeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Additional contraindications for patients with psoriasis or rheumatoid arthritis: Pregnancy, alcoholism, alcoholic liver disease or other chronic liver disease, immunodeficiency syndrome (overt or laboratory evidence); pre-existing blood dyscrasias (eg, bone marrow hypoplasia, leukopenia, thrombocytopenia, significant anemia)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute renal failure:",
"     <b>",
"      [U.S. Boxed Warning]: May cause renal damage leading to acute renal failure, especially with high-dose methotrexate;",
"     </b>",
"     monitor renal function and methotrexate levels closely, maintain adequate hydration and urinary alkalinization. Use caution in osteosarcoma patients treated with high-dose methotrexate in combination with nephrotoxic chemotherapy (eg, cisplatin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Bone marrow suppression may occur,",
"     </b>",
"     resulting in anemia, aplastic anemia, pancytopenia, leukopenia, neutropenia, and/or thrombocytopenia. Use caution in patients with pre-existing bone marrow suppression. Discontinue treatment  (immediately) in RA or psoriasis if a significant decrease in hematologic components is noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Any dose level or route of administration may cause severe and potentially fatal dermatologic reactions,",
"     </b>",
"     including toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis, skin necrosis, and erythema multiforme. Radiation dermatitis and sunburn may be precipitated by methotrexate administration. Psoriatic lesions may be worsened by concomitant exposure to ultraviolet radiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea/stomatitis:",
"     <b>",
"      [U.S. Boxed Warning]: Diarrhea and ulcerative stomatitis may require treatment interruption;",
"     </b>",
"     death from hemorrhagic enteritis or intestinal perforation has been reported. Use with caution in patients with peptic ulcer disease, ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fertility:  May cause impairment of fertility, oligospermia, and menstrual dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Methotrexate has been associated with acute (elevated transaminases) and potentially fatal chronic (fibrosis, cirrhosis) hepatotoxicity.",
"     </b>",
"     Risk is related to cumulative dose (&ge;1.5 g) and prolonged exposure. Monitor closely (with liver function tests, including serum albumin) for liver toxicities. Liver enzyme elevations may be noted, but may not be predictive of hepatic disease in long term treatment for psoriasis (but generally is predictive in rheumatoid arthritis [RA] treatment). With long-term use, liver biopsy may show histologic changes, fibrosis, or cirrhosis; periodic liver biopsy is recommended with long-term use for psoriasis patients with risk factors for hepatotoxicity  and for persistent abnormal liver function tests in psoriasis patients without risk factors for hepatotoxicity and in  RA patients; discontinue methotrexate with moderate-to-severe change in liver biopsy. Risk factors for hepatotoxicity include history of above moderate ethanol consumption, persistent abnormal liver chemistries, history of chronic liver disease (including hepatitis B or C), family history of inheritable liver disease, diabetes, obesity, hyperlipidemia, lack of folate supplementation during methotrexate therapy, cumulative methotrexate dose exceeding 1.5 g, continuous daily dosing of methotrexate and history of significant exposure to hepatotoxic drugs. Use caution with preexisting liver impairment; may require dosage reduction. Use caution when used with other hepatotoxic agents (azathioprine, retinoids, sulfasalazine).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lymphomas:",
"     <b>",
"      [U.S. Boxed Warning]: Use of low dose methotrexate has been associated with the development of malignant lymphomas;",
"     </b>",
"     may regress upon treatment discontinuation; treat lymphoma appropriately if regression is not induced by cessation of methotrexate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: May cause neurotoxicity including seizures (usually in pediatric ALL patients receiving intermediate-dose methotrexate (1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     ), leukoencephalopathy (usually with concurrent cranial irradiation) and stroke-like encephalopathy (usually with high-dose regimens). Chemical arachnoiditis (headache, back pain, nuchal rigidity, fever), myelopathy and chronic leukoencephalopathy may result from intrathecal administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Opportunistic infections:",
"     <b>",
"      [U.S. Boxed Warning]:",
"     </b>",
"     <b>",
"      Immune suppression may lead to potentially fatal opportunistic infections.",
"     </b>",
"     Use methotrexate with extreme caution in patients with an active infection (contraindicated in patients with immunodeficiency syndrome).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pneumonitis:",
"     <b>",
"      [U.S. Boxed Warning]: May cause potentially life-threatening pneumonitis",
"     </b>",
"     (may occur at any time during therapy and at any dosage); monitor closely for pulmonary symptoms, particularly dry, nonproductive cough. Other potential symptoms include fever, dyspnea, hypoxemia, or pulmonary infiltrate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome:",
"     <b>",
"      [U.S. Boxed Warning]:  Tumor lysis syndrome may occur in patients with high tumor burden;",
"     </b>",
"     use appropriate prevention and treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ascites/pleural effusions:",
"     <b>",
"      [U.S. Boxed Warning]: Elimination is reduced in patients with ascites and/or pleural effusions;",
"     </b>",
"     resulting in prolonged half-life and toxicity; may require dose reduction or discontinuation. Monitor closely for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with pre-existing liver impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patients with peptic ulcer disease; diarrhea and stomatitis may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Methotrexate elimination is reduced in patients with renal impairment;",
"     </b>",
"     may require dose reduction or discontinuation; monitor closely for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative colitis: Use with caution in patients with ulcerative colitis; diarrhea and stomatitis may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxic agents: Use caution when used with other hepatotoxic agents (azathioprine, retinoids, sulfasalazine).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxic chemotherapy: Use caution in osteosarcoma patients treated with high-dose methotrexate in combination with nephrotoxic chemotherapy (eg, cisplatin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NSAIDs:",
"     <b>",
"      [U.S. Boxed Warning]: Concurrent administration with NSAIDs may cause severe bone marrow suppression, aplastic anemia, and GI toxicity.",
"     </b>",
"     Do not administer NSAIDs prior to or during high dose methotrexate therapy; may increase and prolong serum methotrexate levels. Doses used for psoriasis may still lead to unexpected toxicities; use caution when administering NSAIDs or salicylates with lower doses of methotrexate for RA. Methotrexate may increase the levels and effects of mercaptopurine; may require dosage adjustments. Vitamins containing folate may decrease response to systemic methotrexate; folate deficiency may increase methotrexate toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proton pump inhibitors: Concomitant use of proton pump inhibitors with methotrexate (primarily high-dose methotrexate) may elevate and prolong serum methotrexate levels and metabolite (hydroxymethotrexate) levels (based on case reports and pharmacokinetic studies). May lead to toxicities; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: Immunization may be ineffective during methotrexate treatment. Immunization with live vaccines is not recommended; cases of disseminated vaccinia infections due to live vaccines have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution and monitor closely in the elderly; increased risk of toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: May cause fetal death or congenital abnormalities; do not use for psoriasis or RA treatment in pregnant women.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiotherapy recipients:",
"     <b>",
"      [U.S. Boxed Warning]: Concomitant methotrexate administration with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Injection may contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Preservative-containing formulations/diluents:",
"     <b>",
"      [U.S. Boxed Warnings]:  Methotrexate formulations and/or diluents containing preservatives should not be used for intrathecal or high-dose  methotrexate  therapy.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration schedules: Errors have occurred (some resulting in death) when methotrexate was administered as &ldquo;daily&rdquo; dose instead of an intended &ldquo;weekly&rdquo; dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warnings]: Should be administered under the supervision of a physician experienced in the use of antimetabolite therapy;",
"     </b>",
"     serious and fatal toxicities have occurred at all dose levels; monitor closely. For rheumatoid arthritis and psoriasis, immunosuppressive therapy should only be used when disease is active and less toxic, traditional therapy is ineffective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intrathecal safety: When used for intrathecal administration, should not be prepared during the preparation of any other agents. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only. Delivery of intrathecal medications to the patient should only be with other medications intended for administration into the central nervous system (Jacobson, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein, SLCO1B1",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May enhance the hepatotoxic effect of Methotrexate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Methotrexate. This may result in nausea, vomiting, oral ulcers, hepatotoxicity and/or nephrotoxicity. Methotrexate may increase the serum concentration of CycloSPORINE (Systemic). This may result in nephrotoxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Methotrexate may enhance the adverse/toxic effect of Leflunomide. Particular concerns are an increased risk of pancytopenia and/or hepatotoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Methotrexate may diminish the therapeutic effect of Loop Diuretics. Methotrexate may increase the serum concentration of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate.  Management: Monitor for increased methotrexate and/or loop diuretic levels/toxicity with concomitant use of these agents and monitor for decreased therapeutic effects of loop diuretics. Methotrexate and/or loop diuretic dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: May enhance the hepatotoxic effect of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Methotrexate. Management: Avoid concomitant use of probenecid and methotrexate if possible.  If used together, consider lower methotrexate doses and monitor for evidence of methotrexate toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sapropterin: Methotrexate may decrease the serum concentration of Sapropterin. Specifically, methotrexate may decrease tissue concentrations of tetrahydrobiopterin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SulfaSALAzine: May enhance the hepatotoxic effect of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the adverse/toxic effect of Methotrexate. Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (eg, bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Methotrexate may increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the adverse/toxic effect of Methotrexate. Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Methotrexate may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F194552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may be associated with increased liver injury. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Methotrexate peak serum levels may be decreased if taken with food. Milk-rich foods may decrease methotrexate absorption. Folate may decrease drug response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Echinacea has immunostimulant properties. Management: Avoid echinacea.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (psoriasis, rheumatoid arthritis) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F194538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Methotrexate may cause fetal death and/or congenital abnormalities.",
"     </b>",
"     Studies in animals and pregnant women have shown evidence of fetal abnormalities; therefore, the manufacturer classifies methotrexate as pregnancy category X (for psoriasis or RA). A pattern of congenital malformations associated with maternal methotrexate use is referred to as the aminopterin/methotrexate syndrome. Features of the syndrome include CNS, skeletal, and cardiac abnormalities. Low birth weight and developmental delay have also been reported. The use of methotrexate may impair fertility and cause menstrual irregularities or oligospermia during treatment and following therapy. Methotrexate is approved for the treatment of trophoblastic neoplasms (gestational choriocarcinoma, chorioadenoma destruens, and hydatidiform mole) and has been used for the medical management of ectopic pregnancy and the medical management of abortion.",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for the treatment of psoriasis or RA in pregnant women.",
"     </b>",
"     Pregnancy should be excluded prior to therapy in women of childbearing potential. Use for the treatment of neoplastic diseases only when the potential benefit to the mother outweighs the possible risk to the fetus. Pregnancy should be avoided for &ge;3 months following treatment in male patients and &ge;1 ovulatory cycle in female patients. A registry is available for pregnant women exposed to autoimmune medications including methotrexate. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F194569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9259798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low amounts of methotrexate are excreted into breast milk. Due to the potential for serious adverse reactions in a breast-feeding infant, use is contraindicated in nursing mothers.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F194539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F194537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Methotrexate Sodium (PF) Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (4 mL): $7.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Methotrexate Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (2 mL): $8.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Methotrexate Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $59.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methotrexate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $356.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Rheumatrex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (16): $187.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Trexall Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $352.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (30): $529.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $705.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (30): $1058.27",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F194524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Laboratory tests should be performed on day 5 or day 6 of the weekly methotrexate cycle (eg, psoriasis, RA) to detect the leukopenia nadir and to avoid elevated LFTs 1-2 days after taking dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patients with psoriasis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CBC with differential and platelets (baseline, 7-14 days after initiating therapy or dosage increase, every 2-4 weeks for first few months, then every 1-3 months); BUN and serum creatinine (baseline and every 2-3 months); consider PPD for latent TB screening (baseline); LFTs (baseline, monthly for first 6 months, then every 1-2 months); chest x-ray (baseline if underlying lung disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Liver biopsy for patients",
"     <b>",
"      with",
"     </b>",
"     risk factors for hepatotoxicity: Baseline or after 2-6 months of therapy and with each 1-1.5 g cumulative dose interval",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Liver biopsy for patients",
"     <b>",
"      without",
"     </b>",
"     risk factors for hepatotoxicity: If persistent elevations in 5 of 9 AST levels during a 12-month period, or decline of serum albumin below the normal range with normal nutritional status. Consider biopsy after cumulative dose of 3.5-4 g and after each additional 1.5 g.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patients with rheumatoid arthritis and Crohn&rsquo;s disease:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CBC with differential and platelets, serum creatinine and LFTs (baseline then every 2-4 weeks for initial 3 months of therapy, then every 8-12 weeks for 3-6 months of therapy and then every 12 weeks after 6 months of therapy); chest x-ray (baseline); pulmonary function test (if methotrexate-induced lung disease suspected); hepatitis B or C testing (baseline)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Liver biopsy: Baseline (if persistent abnormal baseline LFTs, history of alcoholism, or chronic hepatitis B or C) or during treatment if persistent LFT elevations (6 of 12 tests abnormal over 1 year or 5 of 9 results when LFTs performed at 6-week intervals)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patients with cancer: Baseline and frequently during treatment: CBC with differential and platelets, serum creatinine, BUN, LFTs; chest x-ray (baseline); methotrexate levels and urine pH (with high-dose therapy); pulmonary function test (if methotrexate-induced lung disease suspected)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ectopic pregnancy (unlabeled use): Prior to therapy, measure serum hCG, CBC with differential, liver function tests, serum creatinine. Serum hCG concentrations should decrease between treatment days 4 and 7. If hCG decreases by &gt;15%, additional courses are not needed however, continue to measure hCG weekly until no longer detectable.  If &lt;15% decrease is observed, repeat dose per regimen (Barnhart, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F194527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic levels: Variable; Toxic concentration: Variable; therapeutic range is dependent upon therapeutic approach.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     High-dose regimens produce drug levels that are between 0.1-1 micromole/L 24-72 hours after drug infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toxic: Low-dose therapy: &gt;0.2 micromole/L; high-dose therapy: &gt;1 micromole/L",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F194540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abitrexate (IL, SG, TH, TW);",
"     </li>",
"     <li>",
"      Artrait (UY);",
"     </li>",
"     <li>",
"      Atrexel (MX);",
"     </li>",
"     <li>",
"      Biotrexate (IN);",
"     </li>",
"     <li>",
"      Brimexate (IT);",
"     </li>",
"     <li>",
"      Canceren (KP);",
"     </li>",
"     <li>",
"      Ebetrexat (BG, SG);",
"     </li>",
"     <li>",
"      Emthexat (SE);",
"     </li>",
"     <li>",
"      Emthexate (AT, BE, GR, MY, NL, NO, PH, PK, PT, TH, TR, TW);",
"     </li>",
"     <li>",
"      Emthexate PF (KP);",
"     </li>",
"     <li>",
"      Lantarel (DE);",
"     </li>",
"     <li>",
"      Ledertrexate (BE, FR, LU, MX, NZ, PT);",
"     </li>",
"     <li>",
"      Maxtrex (GB);",
"     </li>",
"     <li>",
"      Medsatrexate (MX);",
"     </li>",
"     <li>",
"      Meisusheng (CL);",
"     </li>",
"     <li>",
"      Methoblastin (AU, NZ);",
"     </li>",
"     <li>",
"      Methotrexat (HR);",
"     </li>",
"     <li>",
"      Methotrexat Bigmar (CH);",
"     </li>",
"     <li>",
"      Methotrexat Ebewe (CH);",
"     </li>",
"     <li>",
"      Methotrexat Farmos (CH);",
"     </li>",
"     <li>",
"      Methotrexat Lachema (HU);",
"     </li>",
"     <li>",
"      Methotrexat Lederle (CH);",
"     </li>",
"     <li>",
"      Methotrexat Teva (CH);",
"     </li>",
"     <li>",
"      Methotrexat-Ebewe (HU);",
"     </li>",
"     <li>",
"      Methotrexat-Teva (HU);",
"     </li>",
"     <li>",
"      Methotrexate (AU, HK, ID, IL, MY, PH, TH, TW);",
"     </li>",
"     <li>",
"      Methotrexate Faulding (SE);",
"     </li>",
"     <li>",
"      Methotrexate Pharmacia (SE);",
"     </li>",
"     <li>",
"      Methotrexate Wyeth Lederle (SE);",
"     </li>",
"     <li>",
"      Methotrexate &rdquo;Lederle&rdquo; (HU);",
"     </li>",
"     <li>",
"      Methotrexate[inj.] (HR, IT);",
"     </li>",
"     <li>",
"      Methotrexato (AR, EC);",
"     </li>",
"     <li>",
"      Meticil (PE);",
"     </li>",
"     <li>",
"      Metoject (CZ, DK, ES, FR);",
"     </li>",
"     <li>",
"      Metotreksat (HR);",
"     </li>",
"     <li>",
"      Metotressato Teva (IT);",
"     </li>",
"     <li>",
"      Metotrexato (CN);",
"     </li>",
"     <li>",
"      Metotrexato DBL (IT);",
"     </li>",
"     <li>",
"      Metotrexin (BR);",
"     </li>",
"     <li>",
"      Metrex (PY);",
"     </li>",
"     <li>",
"      Mexat (CO);",
"     </li>",
"     <li>",
"      Midu (CL);",
"     </li>",
"     <li>",
"      MTX Hexal (LU);",
"     </li>",
"     <li>",
"      Neotrexate (IN);",
"     </li>",
"     <li>",
"      Novatrex (FR);",
"     </li>",
"     <li>",
"      Onkomet (TH);",
"     </li>",
"     <li>",
"      Otaxem (MX);",
"     </li>",
"     <li>",
"      P&amp;U Methotrexate (ZA);",
"     </li>",
"     <li>",
"      Pterin (PH);",
"     </li>",
"     <li>",
"      Reumatrex (PE);",
"     </li>",
"     <li>",
"      Texate (MX);",
"     </li>",
"     <li>",
"      Trexan (EE, FI, HN, HU, PL, RU, TR, TW);",
"     </li>",
"     <li>",
"      Trixilem (MX, TH);",
"     </li>",
"     <li>",
"      Zexate (PH, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F194514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methotrexate is a folate antimetabolite that inhibits DNA synthesis, repair, and cellular replication. Methotrexate irreversibly binds to dihydrofolate reductase, inhibiting the formation of reduced folates, and thymidylate synthetase, resulting in inhibition of purine and thymidylic acid synthesis. Methotrexate is cell cycle specific for the S phase of the cycle.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The MOA in the treatment of rheumatoid arthritis is unknown, but may affect immune function. In psoriasis, methotrexate is thought to target rapidly proliferating epithelial cells in the skin.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     In Crohn&rsquo;s disease, it may have immune modulator and anti-inflammatory activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F194533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antirheumatic: 3-6 weeks; additional improvement may continue longer than 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Highly variable; dose dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. injection: Complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Penetrates slowly into 3rd space fluids (eg, pleural effusions, ascites), exits slowly from these compartments (slower than from plasma); sustained concentrations retained in kidney and liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : I.V.: 0.18 L/kg (initial); 0.4-0.8 L/kg (steady state)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially metabolized by intestinal flora (after oral administration) to DAMPA by carboxypeptidase; hepatic aldehyde oxidase converts methotrexate to 7-hydroxy methotrexate; polyglutamates are produced intracellularly and are just as potent as methotrexate; their production is dose- and duration-dependent and they are slowly eliminated by the cell once formed. Polyglutamated forms can be converted back to methotrexate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: ~20% to 95%; in general, bioavailability is dose dependent and decreases as the dose increases (especially at doses &ge;80 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Low dose: 3-10 hours; High dose: 8-15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 1-2 hours; I.M.: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Dose and route dependent; I.V.: Urine (80% to 90% as unchanged drug; 5% to 7% as 7-hydroxy methotrexate); feces (&lt;10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Practice Bulletin. Clinical Management Guidelines of Obstetrician-Gynecologists. Number 67, October 2005. &ldquo;Medical Management of Abortion,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 106(4):871-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/16199653/pubmed\" id=\"16199653\" target=\"_blank\">",
"        16199653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ad&egrave;s L, Sanz MA, Chevret S, et al, &ldquo;Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison of French-Belgian-Swiss and PETHEMA Results,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(3):1078-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/17975017/pubmed\" id=\"17975017\" target=\"_blank\">",
"        17975017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Alfadhli AA, McDonald JW, and Feagan BG, &ldquo;Methotrexate for Induction of Remission in Refractory Crohn's Disease,&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2005, 25(1):CD003459.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/15674908/pubmed\" id=\"15674908\" target=\"_blank\">",
"        15674908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines,  &ldquo;Guidelines for the Management of Rheumatoid Arthritis: 2002 Update,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2002, 46(2):328&ndash;46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/11840435/pubmed\" id=\"11840435\" target=\"_blank\">",
"        11840435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 101.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Azzarelli A, Gronchi A, Bertulli R, et al, &ldquo;Low-Dose Chemotherapy With Methotrexate and Vinblastine for Patients With Advanced Aggressive Fibromatosis,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2001, 92(5):1259-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/11571741/pubmed\" id=\"11571741\" target=\"_blank\">",
"        11571741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barnhart KT, &ldquo;Clinical Practice. Ectopic Pregnancy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      ,  2009, 361(4):379-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/19625718/pubmed\" id=\"19625718\" target=\"_blank\">",
"        19625718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartz D and Goldberg A, &ldquo;Medication Abortion,&rdquo;",
"      <i>",
"       Clin Obstet Gynecol",
"      </i>",
"      , 2009, 52(2):140-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/19407520/pubmed\" id=\"19407520\" target=\"_blank\">",
"        19407520",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bleyer WA, Coccia PF, Sather HN, et al, &ldquo;Reduction in Central Nervous System Leukemia With a Pharmacokinetically Derived Intrathecal Methotrexate Dosage Regimen,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1983, 1(5):317-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/6366138/pubmed\" id=\"6366138\" target=\"_blank\">",
"        6366138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Braun J, K&auml;stner P, Flaxenberg P, et al, &ldquo;Comparison of the Clinical Efficacy and Safety of Subcutaneous Versus Oral Administration of Methotrexate in Patients With Active Rheumatoid Arthritis: Results of a Six-Month, Multicenter, Randomized, Double-Blind, Controlled, Phase IV Trial,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2008, 58(1):73-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/18163521/pubmed\" id=\"18163521\" target=\"_blank\">",
"        18163521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Briemberg HR and Amato AA, &ldquo;Dermatomyositis and Polymyositis,&rdquo;",
"      <i>",
"       Curr Treat Options Neurol",
"      </i>",
"      , 2003, 5(5):349-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/12895397/pubmed\" id=\"12895397\" target=\"_blank\">",
"        12895397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chao NJ, Schmidt GM, Niland JC, et al, &ldquo;Cyclosporine, Methotrexate, and Prednisone Compared with Cyclosporine and Prednisone for Prophylaxis of Acute Graft-versus-Host Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(17):1225-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/8413388/pubmed\" id=\"8413388\" target=\"_blank\">",
"        8413388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chao NJ, Snyder DS, Jain M, et al, &ldquo;Equivalence of 2 Effective Graft-Versus-Host Disease Prophylaxis Regimens: Results of a Prospective Double-Blind Randomized Trial,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2000, 6(3):254-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/10871150/pubmed\" id=\"10871150\" target=\"_blank\">",
"        10871150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      deLemos ML, Monfared S, Denyssevych T, et al. &ldquo;Evaluation of Osmolality and pH of Various Concentrations of Methotrexate, Cytarabine, and Thiotepa Prepared in Normal Saline, Sterile Water for Injection, and Lactated Ringer's Solution for Intrathecal Administration,&rdquo;",
"      <i>",
"       J Oncol Pharm Pract",
"      </i>",
"      , 2009, 15(1):45-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/18772215/pubmed\" id=\"18772215\" target=\"_blank\">",
"        18772215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Egan LJ, Sandborn WJ, Tremaine WJ, et al, &ldquo;A Randomized Dose-Response and Pharmacokinetic Study of Methotrexate for Refractory Inflammatory Crohn's Disease and Ulcerative Colitis,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 1999, 13(12):1597-604.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/10594394/pubmed\" id=\"10594394\" target=\"_blank\">",
"        10594394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Evans WE, Pratt CB, Taylor RH, et al, &ldquo;Pharmacokinetic Monitoring of High-Dose Methotrexate: Early Recognition of High-Risk Patients,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1979, 3:161-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/316744/pubmed\" id=\"316744\" target=\"_blank\">",
"        316744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feagan BG, Fedorak RN, Irvine EJ, et al, &ldquo;A Comparison of Methotrexate With Placebo for the Maintenance of Remission in Crohn's Disease. North American Crohn's Study Group Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(22):1627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/10833208/pubmed\" id=\"10833208\" target=\"_blank\">",
"        10833208",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furst DE, &ldquo;Methotrexate: New Mechanisms and Old Toxicities,&rdquo;",
"      <i>",
"       Agents Actions Suppl",
"      </i>",
"      , 1993, 44:131-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/8396846/pubmed\" id=\"8396846\" target=\"_blank\">",
"        8396846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glantz MJ, Cole BF, Recht L, Akerley W, et al, &ldquo;High-Dose Intravenous Methotrexate for Patients With Nonleukemic Leptomeningeal Cancer: Is Intrathecal Chemotherapy Necessary?&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(4):1561-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/9552066/pubmed\" id=\"9552066\" target=\"_blank\">",
"        9552066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glantz MJ, Jaeckle KA, Chamberlain MC, et al, &ldquo;A Randomized Controlled Trial Comparing Intrathecal Sustained-Release Cytarabine (DepoCyt) to Intrathecal Methotrexate in Patients With Neoplastic Meningitis from Solid Tumors,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 1999, 5(11):3394-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/10589750/pubmed\" id=\"10589750\" target=\"_blank\">",
"        10589750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grem JL, King SA, Wittes RE, et al, &ldquo;The Role of Methotrexate in Osteosarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 1988, 80(9):626-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/3286880/pubmed\" id=\"3286880\" target=\"_blank\">",
"        3286880",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grossman SA, Finkelstein DM, Ruckeschel JC, et al, &ldquo;Randomized Prospective Comparison of Intraventricular Methotrexate and Thiotepa in Patients With Previously Untreated Neoplastic Meningitis. Eastern Cooperative Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol,",
"      </i>",
"      1993, 11(3):561-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/8445432/pubmed\" id=\"8445432\" target=\"_blank\">",
"        8445432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for Referral and Management of Systemic Lupus Erythematosus in Adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1999, 42(9):1785-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/10513791/pubmed\" id=\"10513791\" target=\"_blank\">",
"        10513791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoang-Xuan K, Taillandier L, Chinot O, et al, &ldquo;Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(14):2726-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/12860951/pubmed\" id=\"12860951\" target=\"_blank\">",
"        12860951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoffman GS, Leavitt RY, Kerr GS, et al, \"Treatment of Glucocorticoid-Resistant or Relapsing Takayasu Arteritis With Methotrexate,\"",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1994, 37(4):578-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/7908520/pubmed\" id=\"7908520\" target=\"_blank\">",
"        7908520",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson JO, Polovich M, McNiff KK, et al, \"American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/19786650/pubmed\" id=\"19786650\" target=\"_blank\">",
"        19786650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jolivet J, Cowan KH, Curt GA, et al, &ldquo;The Pharmacology and Clinical Use of Methotrexate,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1983, 309(18):1094-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/6353235/pubmed\" id=\"6353235\" target=\"_blank\">",
"        6353235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kalb RE, Strober B, Weinstein G, et al, &ldquo;Methotrexate and Psoriasis: 2009 National Psoriasis Foundation Consensus Conference,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2009, 60(5):824-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/19389524/pubmed\" id=\"19389524\" target=\"_blank\">",
"        19389524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kerr JZ, Berg S, and Blaney SM, &ldquo;Intrathecal Chemotherapy,&rdquo;",
"      <i>",
"       Crit Rev Oncol Hematol",
"      </i>",
"      , 2001, 37(3):227-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/11248578/pubmed\" id=\"11248578\" target=\"_blank\">",
"        11248578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kremer JM, Alarcon GS, Lightfoot RW Jr, et al, &ldquo;Methotrexate for Rheumatoid Arthritis. Suggested Guidelines for Monitoring Liver Toxicity. American College of Rheumatology,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1994, 37(3):316-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/8129787/pubmed\" id=\"8129787\" target=\"_blank\">",
"        8129787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lacasce A, Howard O, Lib S, et al, &ldquo;Modified Magrath Regimens for Adults With Burkitt and Burkitt-Like Lymphomas: Preserved Efficacy With Decreased Toxicity,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2004, 45(4):761-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/15160953/pubmed\" id=\"15160953\" target=\"_blank\">",
"        15160953",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee SL, Neskey D, and Mouzakes J, &ldquo;Potential Predisposition for Nasal Septal Perforation With Methotrexate Use: Report of 2 Cases and Literature Review,&rdquo;",
"      <i>",
"       Ear Nose Throat J",
"      </i>",
"      , 2009, 88(8):E12-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/19688702/pubmed\" id=\"19688702\" target=\"_blank\">",
"        19688702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):465-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/19174807/pubmed\" id=\"19174807\" target=\"_blank\">",
"        19174807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lin WY, Liu HC, Yeh TC, et al, &ldquo;Triple Intrathecal Therapy Without Cranial Irradiation for Central Nervous System Preventive Therapy in Childhood Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2008, 50(3):523-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/17455314/pubmed\" id=\"17455314\" target=\"_blank\">",
"        17455314",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, &ldquo;Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2012, 308(9): 898-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/22948700/pubmed\" id=\"22948700\" target=\"_blank\">",
"        22948700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Menter A, Korman NJ, Elmets CA, et al, &ldquo;Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 4. Guidelines of Care for the Management and Treatment of Psoriasis With Traditional Systemic Agents,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2009, 61(3):451-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/19493586/pubmed\" id=\"19493586\" target=\"_blank\">",
"        19493586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Iser JH, and Gibson PR, &ldquo;A Single Center Experience of Methotrexate in the Treatment of Crohn&rsquo;s Disease and Ulcerative Colitis: A Case for Subcutaneous Administration,&rdquo;",
"      <i>",
"       Gastroenterol",
"      </i>",
"      , 2008, 23(6):954-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/17559377/pubmed\" id=\"17559377\" target=\"_blank\">",
"        17559377",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Central Nervous System Cancers,&rdquo; Version 1.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/cns.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newman ED and Scott DW, &ldquo;The Use of Low-dose Oral Methotrexate in the Treatment of Polymyositis and Dermatomyositis,&rdquo;",
"      <i>",
"       J Clin Rheumatol",
"      </i>",
"      , 1995, 1(2):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/19077954/pubmed\" id=\"19077954\" target=\"_blank\">",
"        19077954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Omuro AM, DeAngelis LM, Yahalom J, et al, &ldquo;Chemoradiotherapy for Primary CNS Lymphoma: An Intent-To-Treat Analysis With Complete Follow-Up,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2005, 64(1):69-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/15642906/pubmed\" id=\"15642906\" target=\"_blank\">",
"        15642906",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ortega JJ, Madero L, Martin G, et al, &ldquo;Treatment With All-",
"      <i>",
"       Trans",
"      </i>",
"      Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7632-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/16234524/pubmed\" id=\"16234524\" target=\"_blank\">",
"        16234524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al, &ldquo;High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non-AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(24):4483-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/14597741/pubmed\" id=\"14597741\" target=\"_blank\">",
"        14597741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ross M, Schmidt GM, Niland JC, et al, &ldquo;Cyclosporine, Methotrexate, and Prednisone Compared With Cyclosporine and Prednisone for Prevention of Acute Graft-vs.-Host Disease: Effect on Chronic Graft-vs.-Host Disease and Long-Term Survival,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 1999, 5(5):285-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/10534058/pubmed\" id=\"10534058\" target=\"_blank\">",
"        10534058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Martin G, Gonzalez M, et al, &ldquo;Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All-",
"      <i>",
"       Trans",
"      </i>",
"      -Retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(4):1237-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/14576047/pubmed\" id=\"14576047\" target=\"_blank\">",
"        14576047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz S, Borner K, Muller K, et al, &ldquo;Glucarpidase (Carboxypeptidase G2) Intervention in Adult and Elderly Cancer Patients With Renal Dysfunction and Delayed Methotrexate Elimination After High-Dose Methotrexate Therapy,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2007 12(11):1299-308.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/18055849/pubmed\" id=\"18055849\" target=\"_blank\">",
"        18055849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seeber BE and Barnhart KT, &ldquo;Suspected Ectopic Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2006, 107(2 Pt 1):399-413.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/16449130/pubmed\" id=\"16449130\" target=\"_blank\">",
"        16449130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(5):625-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/22473917/pubmed\" id=\"22473917\" target=\"_blank\">",
"        22473917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sternberg CN, de Mulder PH, Schornagel JH, et al, &ldquo;Randomized Phase III Trial of High-Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(10):2638-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/11352955/pubmed\" id=\"11352955\" target=\"_blank\">",
"        11352955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treon SP and Chabner BA, &ldquo;Concepts in Use of High-Dose Methotrexate Therapy,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1996, 42(8 Pt 2):1322-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/8697606/pubmed\" id=\"8697606\" target=\"_blank\">",
"        8697606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Roon EN and van de Laar MA, \"Methotrexate Bioavailability,&rdquo;",
"      <i>",
"       Clin Exp Rheumatol",
"      </i>",
"      , 2010, 28(Suppl 61):27-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/21044430/pubmed\" id=\"21044430\" target=\"_blank\">",
"        21044430",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Visser K, Katchamart W, Loza A, et al, &ldquo;Multinational Evidence-Based Recommendations for the Use of Methotrexate in Rheumatic Disorders With a Focus on Rheumatoid Arthritis: Integrating Systematic Literature Research and Expert Opinion of a Broad International Panel of Rheumatologists in the 3E Initiative,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      ,  2009, 68(7):1086&ndash;93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/19033291/pubmed\" id=\"19033291\" target=\"_blank\">",
"        19033291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widemann BC, Balis FM, Murphy RF, et al, &ldquo;Carboxypeptidase-G2, Thymidine, and Leucovorin Rescue in Cancer Patients With Methotrexate-Induced Renal Dysfunction,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(5):2125-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/9164227/pubmed\" id=\"9164227\" target=\"_blank\">",
"        9164227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widemann BC, Balis FM, Shalabi A, et al, &ldquo;Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2004, 96(20):1557-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/15494606/pubmed\" id=\"15494606\" target=\"_blank\">",
"        15494606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiendl H, &ldquo;Idiopathic Inflammatory Myopathies: Current and Future Therapeutic  Options,&rdquo;",
"      <i>",
"       Neurotherapeutics",
"      </i>",
"      , 2008, 5(4):548-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/38/24170/abstract-text/19019306/pubmed\" id=\"19019306\" target=\"_blank\">",
"        19019306",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9630 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-197.136.42.3-858ECED34C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24170=[""].join("\n");
var outline_f23_38_24170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709040\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194555\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194556\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194602\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194560\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194583\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194561\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194562\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194563\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15255058\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194526\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194511\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194531\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194608\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194530\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854604\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194611\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194600\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194534\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194515\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837690\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194520\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194552\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194522\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194538\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194569\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9259798\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194539\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194537\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194524\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194527\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194540\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194514\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194533\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9630\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9630|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=related_link\">",
"      Methotrexate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=related_link\">",
"      Methotrexate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_38_24171="Time at which PCI loses survival superiority over fibrinolysis";
var content_f23_38_24171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Time at which PCI loses superiority in survival over fibrinolysis varies depending upon patient risk",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Pre-hospital delay (minutes)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Age &lt;65 years",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Age &ge;65 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Anterior infarction",
"       </td>",
"       <td class=\"subtitle2\">",
"        Non-anterior infarction",
"       </td>",
"       <td class=\"subtitle2\">",
"        Anterior infarction",
"       </td>",
"       <td class=\"subtitle2\">",
"        Non-anterior infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0-120",
"       </td>",
"       <td>",
"        39 minutes",
"       </td>",
"       <td>",
"        56 minutes",
"       </td>",
"       <td>",
"        109 minutes",
"       </td>",
"       <td>",
"        154 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        121+",
"       </td>",
"       <td>",
"        50 minutes",
"       </td>",
"       <td>",
"        103 minutes",
"       </td>",
"       <td>",
"        142 minutes",
"       </td>",
"       <td>",
"        183 minutes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006; 114:2019. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24171=[""].join("\n");
var outline_f23_38_24171=null;
var title_f23_38_24172="Tips for specific patient impairments";
var content_f23_38_24172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips to address specific impairments that may impede patient-physician communication",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Impairment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Helpful material, resources, or personnel",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Hearing",
"       </td>",
"       <td>",
"        <p>",
"         Ask the patient: \"Can you hear me okay the way I'm speaking now?\"",
"        </p>",
"        <p>",
"         Speak slowly and clearly, but don't over-exaggerate words.",
"        </p>",
"        <p>",
"         Face the patient to allow lip-reading.",
"        </p>",
"        <p>",
"         As you increase the volume of your voice, try to keep pitch low (higher frequencies are more impaired in presbycusis).",
"        </p>",
"        <p>",
"         Minimize ambient noise.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Portable amplifiers*",
"        </p>",
"        <p>",
"         Written instructions or educational material",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Vision",
"       </td>",
"       <td>",
"        <p>",
"         Avoid communication that relies on gestures: \"Place your urine sample over there\" or \"Can you do this with your hands?\"",
"        </p>",
"        <p>",
"         Be aware that the patient may miss subtle body language or facial expressions (a smile or an empathic nod). Use words to share those emotions.",
"        </p>",
"        <p>",
"         If you offer a hand, tell the patient so he/she can return the gesture. Likewise, tell the patient when you enter and leave the room.",
"        </p>",
"        <p>",
"         If there are multiple people in the room, speak the patient's name to signify that you are addressing him/her.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Large-print forms and patient education material",
"        </p>",
"        <p>",
"         Reading glasses/magnifiers available",
"        </p>",
"        <p>",
"         Audio-recorded information or personnel to read consent forms or other materials",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cognitive",
"       </td>",
"       <td>",
"        <p>",
"         Stick to the point.",
"        </p>",
"        <p>",
"         When questions are repeated, answer them again, just as you did the first time.",
"        </p>",
"        <p>",
"         Involve caregiver or companion when available and appropriate, but avoid excluding the patient.",
"        </p>",
"        <p>",
"         Write down key instructions and findings for the patient to take home and refer to later.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Take-home education materials",
"        </p>",
"        <p>",
"         Nurses or other extended care providers to reinforce teaching and assess patient's understanding on issues discussed",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If an amplifier is unavailable, you can place the ear pieces of your stethoscope into the patient's ears and speak into the bell.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24172=[""].join("\n");
var outline_f23_38_24172=null;
var title_f23_38_24173="Empiric rx serious SA child";
var content_f23_38_24173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parenteral antimicrobial agents for empiric treatment of bacteremia and other serious Staphylococcus aureus infections in infants and children older than 30 days",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antimicrobial agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Life-threatening infections*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Regimen of choice",
"       </td>",
"       <td>",
"        <p>",
"         Vancomycin +",
"        </p>",
"        <p>",
"         Nafcillin or oxacillin &plusmn;",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Vancomycin: 60 mg/kg per day in 4 doses; maximum daily dose 4 g",
"        </p>",
"        <p>",
"         Nafcillin: 150 to 200 mg/kg per day in 4 doses; maximum daily dose 4 to 12 g",
"        </p>",
"        <p>",
"         Oxacillin: 150 to 200 mg/kg per day in 4 to 6 doses; maximum daily dose 4 to 12 g",
"        </p>",
"        <p>",
"         Gentamicin: 3 mg/kg per day in 3 doses",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternate regimen",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Linezolid &plusmn;",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Linezolid: &lt;12 years: 30 mg/kg per day in 3 doses; &ge;12 years: 600 mg twice per day",
"        </p>",
"        <p>",
"         Gentamicin: 3 mg/kg per day in 3 doses",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Nonlife-threatening infection without signs of shock",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Prevalence of MRSA infection in community &lt;5 to 10 percent",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Nafcillin,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         150 to 200 mg/kg per day in 4 doses; maximum daily dose 4 to 12 g",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxacillin",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        150 to 200 mg/kg per day in 4 to 6 doses; maximum daily dose 4 to 12 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Prevalence of MRSA infection in community &gt;5 to 10 percent and prevalence of clindamycin resistance in community is low",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Clindamycin,",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         30 to 40 mg/kg per day in 3 to 4 doses; maximum daily dose 1.2 to 2.7 g",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Vancomycin",
"       </td>",
"       <td>",
"        60 mg/kg per day in 4 doses; maximum daily dose 4 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Risk factors for healthcare-associated infection",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Vancomycin",
"       </td>",
"       <td>",
"        60 mg/kg per day in 4 doses; maximum daily dose 4 g",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRSA: methicillin-resistant",
"     <em>",
"      Staphylococcus aureus",
"     </em>",
"     .",
"     <br>",
"      * Septic shock, endocarditis, central nervous system infection.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Gentamicin may be added for suspected infected endocarditis, although there are no data from controlled trials to indicate that combination therapy is advantageous.",
"       <br>",
"        &Delta; For patients who have received several courses of vancomycin in recent past.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         Skin infection, cellulitis, osteomyelitis, septic arthritis.",
"         <br>",
"          &sect; Others may choose to provide coverage for MRSA at different prevalence levels.",
"          <br>",
"           &yen; Patients allergic to penicillins and cephalosporins should receive vancomycin as empiric therapy for serious infection.",
"           <br>",
"            &Dagger; Risk factors for healthcare-associated infection include personal history of or frequent contact with an individual with a history of hospitalization, surgery, dialysis, or residence in a long-term care facility within the previous year, frequent contact with the healthcare environment, presence of an invasive device (eg, intravascular catheter or tracheal tube), history of MRSA infection or colonization.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Staphylococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29",
"        <sup>",
"         th",
"        </sup>",
"        ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.653.",
"       </li>",
"       <li>",
"        American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29",
"        <sup>",
"         th",
"        </sup>",
"        ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.807.",
"       </li>",
"       <li>",
"        Liu C, Bayer A, Cosgrove SE, et, al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24173=[""].join("\n");
var outline_f23_38_24173=null;
var title_f23_38_24174="Schematic of CAVHD";
var content_f23_38_24174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Schematic diagram showing continuous arteriovenous hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24174=[""].join("\n");
var outline_f23_38_24174=null;
var title_f23_38_24175="Heart stent PI";
var content_f23_38_24175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Heart stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A heart stent is a tiny metal tube that helps prop open an artery in the heart. It is placed inside an artery during an angioplasty. Most stents are coated with a medicine that helps keep the artery from getting narrow or blocked again.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_38_24175=[""].join("\n");
var outline_f23_38_24175=null;
